Undesired effects	1
a combinatorial treatment for spinal cord injury	22
a combinatorial treatment	22
spinal cord injury	52
transplantation of olfactory ensheathing cells	73
transplantation	73
olfactory ensheathing cells	92
BDNF infusion	124
the red nucleus Frederic Bretzner	141
Jie Liu	177
Erin Currie	186
A. Jane Roskams	199
Wolfram Tetzlaff ICORD	219
International Collaboration	243
Repair Discoveries	274
Departments of Zoology and Surgery	295
Departments	295
Zoology and Surgery	310
University of British Columbia , Vancouver , BC V6T 1Z4	331
University	331
British Columbia , Vancouver , BC V6T 1Z4	345
Canada Keywords	386
BDNF	403
cell body treatment	409
olfactory ensheathing cells	430
rat	459
regeneration	464
spinal cord injury Abstract Transplantations of olfactory ensheathing cells	478
spinal cord injury Abstract Transplantations	478
olfactory ensheathing cells	527
OECs	556
axonal regeneration and functional recovery	592
regeneration	599
spinal cord injury	642
limited growth promotion of rat rubrospinal axons	684
limited growth promotion	684
rat rubrospinal axons	712
a cervical dorsolateral funiculus crush	740
Rubrospinal neurons	781
massive atrophy	809
cervical axotomy	831
only transient expression of regenerationassociated genes	857
only transient expression	857
regenerationassociated genes	886
Cell body treatment with brain-derived neurotrophic factor -LRB- BDNF -RRB-	916
Cell body treatment with brain-derived neurotrophic factor	916
Cell body treatment	916
brain-derived neurotrophic factor	941
BDNF	976
this atrophy	991
regenerationassociated gene expression	1016
regeneration of rubrospinal axons	1068
regeneration	1068
rubrospinal axons	1084
peripheral nerve transplants	1107
we	1143
the failure	1164
rubrospinal axons	1179
a bridge of OEC transplants	1219
a bridge	1219
OEC transplants	1231
this weak intrinsic cell body response	1258
we	1305
BDNF treatment of rubrospinal neurons	1317
BDNF treatment	1317
rubrospinal neurons	1335
transplantation	1360
highly enriched OECs	1379
the nasal mucosa	1413
axonal regeneration as well as behavioral changes	1443
axonal regeneration	1443
behavioral changes	1474
a cervical dorsolateral funiculus crush	1499
Each treatment alone as well as their combination	1540
Each treatment alone	1540
Each treatment	1540
their combination	1572
the dieback of the rubrospinal axons	1600
the dieback	1600
the rubrospinal axons	1615
none of them	1642
none	1642
them	1650
rubrospinal regeneration	1664
the lesion ⁄ transplantation site	1696
Motor performance	1731
a food-pellet	1752
test and forelimb usage	1775
vertical exploration -LRB- cylinder test -RRB-	1806
vertical exploration	1806
cylinder test	1828
transplantation of OECs with BDNF treatment	1878
transplantation	1878
OECs with BDNF treatment	1897
OECs	1897
BDNF treatment	1907
This impaired motor performance	1923
lowered sensory thresholds	1971
animals	2001
the combinatorial therapy	2019
each treatment	2072
Only this combinatorial treatment group	2094
calcitonin gene-related peptide-positive axons rostral	2163
the lesion site	2221
some combinatorial treatments , such as OECs with BDNF ,	2245
some combinatorial treatments	2245
OECs with BDNF	2284
OECs	2284
BDNF	2294
undesired effects in the injured spinal cord	2309
undesired effects	2309
the injured spinal cord	2330
Introduction	2356
Olfactory ensheathing cells -LRB- OECs -RRB-	2369
Olfactory ensheathing cells	2369
OECs	2398
the olfactory bulb	2417
OB	2437
axonal regeneration , remyelination	2471
axonal regeneration	2471
remyelination	2492
functional recovery	2518
various types	2544
spinal cord injury	2561
Li	2581
et al. , 1997 ; Ramon-Cueto et al.	2584
et al. , 1997	2584
et al.	2584
1997	2592
Ramon-Cueto et al.	2598
Ramon-Cueto	2598
et al.	2610
1998 , 2000 ; Nash et al. , 2002 ; Keyvan-Fouladi et al. , 2003 ; Sasaki et al.	2618
1998 , 2000	2618
1998	2618
2000	2624
Nash et al. , 2002	2630
Nash	2630
et al. , 2002	2635
et al.	2635
2002	2643
Keyvan-Fouladi et al. , 2003	2649
Keyvan-Fouladi	2649
et al. , 2003	2664
et al.	2664
2003	2672
Sasaki et al.	2678
Sasaki	2678
et al.	2685
2004 , 2006a	2693
2004	2693
2006a	2699
Claims of the clinical benefits of OECs in spinal cord injury	2707
Claims	2707
the clinical benefits of OECs in spinal cord injury	2717
the clinical benefits	2717
OECs in spinal cord injury	2742
OECs	2742
spinal cord injury	2750
several clinical centers -LRB- Huang et al. , 2003 ; Amador & Guest , 2005 -RRB-	2787
several clinical centers	2787
Huang	2813
et al. , 2003 ; Amador & Guest , 2005	2819
et al.	2819
2003 ; Amador & Guest	2827
2003	2827
Amador & Guest	2833
2005	2849
these treatments	2865
rigorous controls and characterization	2887
the actual cells transplanted	2929
Dobkin	2960
et al. , 2006 ; Guest et al. , 2006	2967
et al.	2967
2006 ; Guest et al.	2975
2006	2975
Guest et al.	2981
Guest	2981
et al.	2987
2006	2995
its greater accessibility	3013
the nasal mucosa	3039
the favored source	3059
OECs	3081
autologous transplantation in humans -LRB- Lu et al. , 2001 , 2002 -RRB-	3090
autologous transplantation	3090
humans -LRB- Lu et al. , 2001 , 2002 -RRB-	3120
humans	3120
Lu	3128
et al. , 2001 , 2002	3131
et al.	3131
2001	3139
2002	3145
We	3152
lamina-propria -LRB- LP -RRB-	3182
lamina-propria	3182
LP	3198
OECs	3210
the mouse nasal mucosa share several similar properties	3220
the mouse nasal mucosa share	3220
those derived from the OB in vitro	3279
those	3279
the OB	3298
Au & Roskams	3315
2003	3329
vivo -LRB- Ramer et al. , 2004a ; Richter et al. , 2005 -RRB-	3349
vivo	3349
Ramer	3355
et al. , 2004a ; Richter et al. , 2005	3361
et al.	3361
2004a ; Richter et al.	3369
2004a	3369
Richter et al.	3376
Richter	3376
et al.	3384
2005	3392
some differences	3418
transplantation -LRB- Richter et al. , 2005 -RRB-	3452
transplantation	3452
Richter	3469
et al. , 2005	3477
et al.	3477
2005	3485
only a few rat rubrospinal axons	3501
mouse LP-OECs but not beyond -LRB- Ramer et al. , 2004a -RRB-	3561
mouse LP-OECs	3561
beyond -LRB- Ramer et al. , 2004a -RRB-	3583
beyond	3583
Ramer	3591
et al. , 2004a	3597
et al.	3597
2004a	3605
rat OB-OECs	3632
brainderived neurotrophic factor -LRB- BDNF ; Ruitenberg et al. , 2003 -RRB-	3659
brainderived neurotrophic factor	3659
BDNF ; Ruitenberg et al. , 2003	3693
BDNF	3693
Ruitenberg et al. , 2003	3699
Ruitenberg	3699
et al. , 2003	3710
et al.	3710
2003	3718
This inability of rubrospinal axons to regenerate	3725
This inability	3725
rubrospinal axons	3743
part	3792
a weakness	3801
the intrinsic cell body response	3815
the red nucleus -LRB- Tetzlaff et al. , 1991 ; Jenkins et al. , 1993 -RRB-	3851
the red nucleus	3851
Tetzlaff	3868
et al. , 1991 ; Jenkins et al. , 1993	3877
et al.	3877
1991 ; Jenkins et al.	3885
1991	3885
Jenkins et al.	3891
Jenkins	3891
et al.	3899
1993	3907
We	3914
cell body treatment of the red nucleus with BDNF	3944
cell body treatment	3944
the red nucleus with BDNF	3967
the red nucleus	3967
BDNF	3988
the atrophy of rubrospinal neurons	4003
the atrophy	4003
rubrospinal neurons	4018
the expression of regeneration - associated genes	4050
the expression	4050
regeneration - associated genes	4068
regeneration	4068
genes	4093
axonal regeneration of the rubrospinal axons	4112
axonal regeneration	4112
the rubrospinal axons	4135
free-ending peripheral nerve transplants	4162
the cervical spinal cord injury site -LRB- Kobayashi et al. , 1997 -RRB-	4216
the cervical spinal cord injury site	4216
Kobayashi	4254
et al. , 1997	4264
et al.	4264
1997	4272
This strategy	4279
1 year	4334
spinal cord injury -LRB- Kwon et al. , 2002 -RRB-	4347
spinal cord injury	4347
Kwon	4367
et al. , 2002	4372
et al.	4372
2002	4380
We	4387
a BDNF-induced enhancement in the rubrospinal cell body response	4418
a BDNF-induced enhancement	4418
the rubrospinal cell body response	4448
regeneration of rubrospinal axons	4497
regeneration	4497
rubrospinal axons	4513
a LP-OEC transplant	4547
functional recovery	4586
the forelimb following a cervical lesion of the spinal cord	4609
the forelimb	4609
a cervical lesion of the spinal cord	4632
a cervical lesion	4632
the spinal cord	4653
this	4680
we	4686
a transplant	4698
highly enriched preparations	4714
LP-OECs derived from the nasal mucosa of green fluorescent protein	4746
LP-OECs	4746
the nasal mucosa of green fluorescent protein	4767
the nasal mucosa	4767
green fluorescent protein	4787
GFP	4814
neonatal mice	4830
a cell body treatment of the red nucleus delivering BDNF for 2 weeks	4849
a cell body treatment	4849
the red nucleus delivering BDNF for 2 weeks	4874
the red nucleus	4874
BDNF for 2 weeks	4901
BDNF	4901
2 weeks	4910
This combinatorial approach	4919
some	4956
rubrospinal axons	4987
their regeneration	5027
LP-OECs	5064
this combined strategy	5087
the functional recovery	5133
the injured forelimb , which correlated with decreased sensory thresholds	5160
the injured forelimb	5160
decreased sensory thresholds	5204
Materials and methods Preparation of LP-OECs from GFP	5235
Materials	5235
methods Preparation of LP-OECs from GFP	5249
methods Preparation	5249
LP-OECs from GFP	5272
LP-OECs	5272
GFP	5285
transgenic mice The preparation of OECs is detailed elsewhere	5289
transgenic mice	5289
The preparation of OECs	5305
The preparation	5305
OECs	5324
Ramer et al. , 2004a	5352
Ramer	5352
et al.	5358
2004a	5366
brief	5377
OECs	5384
the olfactory mucosa of postnatal day 5 transgenic mice	5409
the olfactory mucosa	5409
postnatal day 5 transgenic mice	5433
decapitation	5476
GFP	5501
the beta-actin promoter	5511
Au & Roskams , 2003 ; Ramer et al. , 2004a ; Richter et al. , 2005	5536
Au & Roskams	5536
2003 ; Ramer et al. , 2004a ; Richter et al.	5548
2003	5548
Ramer et al. , 2004a ; Richter et al.	5554
Ramer	5554
et al. , 2004a ; Richter et al.	5560
et al. , 2004a	5560
et al.	5560
2004a	5568
Richter et al.	5575
Richter	5575
et al.	5583
2005	5591
The entire olfactory mucosa , including turbinates and septum ,	5598
The entire olfactory mucosa	5598
turbinates and septum	5637
turbinates	5637
septum	5652
one pup	5679
0.6 mg ⁄ mL collagenase D -LRB- Roche Products , Indianapolis , IN , USA -RRB-	5730
0.6 mg ⁄	5730
mL collagenase D -LRB- Roche Products , Indianapolis , IN , USA -RRB-	5739
mL collagenase D	5739
Roche Products , Indianapolis , IN , USA	5757
Roche Products	5757
Indianapolis , IN	5773
Indianapolis	5773
USA	5791
50 µg ⁄ mL dispase I -LRB- Roche Products -RRB-	5797
50 µg ⁄	5797
mL dispase I -LRB- Roche Products -RRB-	5805
mL dispase I	5805
Roche Products	5819
15 µg ⁄ mL hyaluronidase -LRB- Sigma , St Louis , MO , USA -RRB-	5836
15 µg	5836
⁄ mL hyaluronidase -LRB- Sigma , St Louis , MO , USA -RRB-	5842
⁄ mL hyaluronidase	5842
Sigma	5862
St Louis	5869
MO , USA	5879
0.5 mg ⁄ mL bovine serum albumin -LRB- MP Biomedicals , Irvine , CA , USA -RRB-	5889
0.5 mg ⁄ mL	5889
bovine serum albumin -LRB- MP Biomedicals , Irvine , CA , USA -RRB-	5901
bovine serum albumin	5901
MP Biomedicals	5923
Irvine	5939
CA , USA	5947
50 U DNase I -LRB- Sigma -RRB-	5960
50 U DNase	5960
I -LRB- Sigma -RRB-	5971
I	5971
Sigma	5974
1 h at 37 °C	5985
1 h	5985
37 °C	5992
centrifugation and plating	6005
Initial plating	6033
MEM-Dvaline	6052
10 % fetal bovine serum -LRB- FBS -RRB-	6065
10 % fetal bovine serum	6065
FBS	6089
100 U ⁄ mL penicillin ⁄ streptomycin -LRB- P ⁄ S -RRB-	6098
100 U ⁄ mL penicillin ⁄ streptomycin	6098
P ⁄ S	6136
a poly-l-lysine substrate without additional mitogens	6148
a poly-l-lysine substrate	6148
additional mitogens	6182
4	6215
5 days	6217
enrichment performed using anti-Thy1.1-mediated complement lysis	6233
enrichment	6233
anti-Thy1.1-mediated complement lysis	6260
the majority of contaminating fibroblasts	6308
the majority	6308
contaminating fibroblasts	6324
Cells	6351
DMEM ⁄ F-12 , 10 % FBS and 100 U ⁄ mL P ⁄ S	6374
DMEM ⁄ F-12	6374
DMEM	6374
F-12	6380
10 % FBS	6386
100 U ⁄ mL P ⁄ S	6398
100 U ⁄ mL P	6398
⁄ S	6411
an additional 4 -- 6 days , when they were again subjected to Thy1	6439
an additional 4	6439
6 days , when they were again subjected to Thy1	6455
6 days	6455
they	6468
Thy1	6497
complement lysis	6514
the same media for an additional 24 -- 48 h prior	6544
the same media for an additional 24	6544
the same media	6544
an additional 24	6563
48 h	6580
transplantation	6594
a subset of cells	6625
a subset	6625
cells	6637
plastic coverslips	6661
antigenic assessment	6694
the same time as harvesting for transplantation	6718
the same time	6718
harvesting for transplantation	6735
harvesting	6735
transplantation	6750
They	6767
as at least 75 % double immunopositive	6786
as at least 75 %	6786
p75	6828
glial fibrillary acidic protein -LRB- GFAP -RRB-	6836
glial fibrillary acidic protein	6836
GFAP	6869
hence the fibroblast portion	6876
fibronectin +	6918
fibronectin	6918
+	6929
p75-negative	6933
25 %	6962
these culture conditions	6973
density of plating media , composition of plating media and plating substrate	6999
density	6999
media , composition of plating media	7018
media	7018
composition of plating media	7025
composition	7025
plating media	7040
substrate	7066
we	7077
OECs	7108
Schwann cells	7137
Richter & Roskams	7171
2008	7190
the dissected nasal mucosa	7206
a small percentage	7245
Schwann cells	7267
cranial nerves	7294
identical conditions	7330
Schwann cells	7361
OECs	7411
very different morphologies , mitosis and migration capabilities	7432
very different morphologies	7432
mitosis	7461
migration capabilities	7473
any significant representation of Schwann cell contamination	7503
any significant representation	7503
Schwann cell contamination	7537
visual inspection	7587
we	7615
a few	7635
Schwann cells	7655
sensory nerves in the mucosa	7674
sensory nerves	7674
the mucosa	7692
this contribution	7704
LP-OECs	7734
a density of 5600 cells ⁄ cm2 into T75 flasks for transplantation	7757
a density	7757
5600 cells ⁄ cm2 into T75 flasks for transplantation	7770
5600 cells	7770
cm2	7783
T75 flasks for transplantation	7792
T75 flasks	7792
transplantation	7807
transplantation	7831
the cells from one T75 flask of LP-OECs	7848
the cells	7848
one T75 flask of LP-OECs	7863
one T75 flask	7863
LP-OECs	7880
0.25 % trypsin ⁄ 1 %	7908
0.25 % trypsin ⁄	7908
EDTA , followed by washing in phosphate-buffered saline -LRB- PBS -RRB-	7927
EDTA	7927
phosphate-buffered saline -LRB- PBS -RRB-	7956
phosphate-buffered saline	7956
PBS	7983
resuspension at a concentration of 100 000 -- 120 000 cells	7992
resuspension	7992
a concentration of 100 000 -- 120 000 cells	8008
a concentration	8008
100 000 -- 120 000 cells	8027
100 000	8027
120 000 cells	8035
µL in DMEM	8051
µL	8051
DMEM	8057
F-12	8063
The total time from dissection to transplantation	8069
The total time	8069
dissection to transplantation	8089
dissection	8089
transplantation	8103
11 to 14 days	8131
initial experiments	8163
fresh prepared OECs	8192
maintenance of phenotype	8222
maintenance	8222
phenotype	8237
cryopreservation of cells -LRB- Ramer et al. , 2004a ; and this study -RRB-	8253
cryopreservation	8253
cells -LRB- Ramer et al. , 2004a ; and this study -RRB-	8273
cells	8273
Ramer	8280
et al. , 2004a ; and this study	8286
et al.	8286
2004a	8294
this study	8305
some experiments	8318
OECs that were cryopreserved	8340
OECs	8340
Spinal cord injury and treatment Animal procedures	8370
Spinal cord injury	8370
treatment Animal procedures	8393
accordance	8439
the guidelines of the Canadian Council for Animal Care	8455
the guidelines	8455
the Canadian Council for Animal Care	8473
the Canadian Council	8473
Animal Care	8498
the Animal Care Committee of the University of British Columbia	8531
the Animal Care Committee	8531
the University of British Columbia	8560
the University	8560
British Columbia	8578
A total of 28 out of 32 animals	8596
A total	8596
28	8607
32 animals	8617
behavioral and histological analysis	8642
Dorsolateral funiculus crush Thirty-two adult male Sprague -- Dawley rats	8680
Dorsolateral funiculus crush	8680
Thirty-two adult male Sprague -- Dawley rats	8709
Dawley	8739
300 -- 400 g	8752
300	8752
400 g	8756
cyclosporine A	8790
10 mg ⁄ kg per day , i.p. ; Novartis Pharmaceuticals , Mississauga , ON , Canada	8806
10 mg ⁄ kg	8806
day , i.p. ; Novartis Pharmaceuticals , Mississauga , ON , Canada	8821
day , i.p.	8821
day	8821
Novartis Pharmaceuticals , Mississauga , ON , Canada	8832
2 days	8883
surgery and each day	8897
surgery	8897
each day	8909
the duration of the experiment	8922
the duration	8922
the experiment	8938
Rats	8954
a mixture	8982
ketamine hydrochloride	8995
70 mg ⁄ kg , i.p. ; Bimeda-MTC , Cambridge , ON , Canada	9019
70 mg	9019
⁄ kg , i.p. ; Bimeda-MTC , Cambridge , ON , Canada	9025
⁄ kg , i.p.	9025
⁄ kg	9025
Bimeda-MTC , Cambridge , ON , Canada	9037
xylazine hydrochloride	9076
10 mg ⁄ kg i.p. ; Bayer , Etobicoke , ON , Canada	9100
10 mg	9100
⁄ kg i.p. ; Bayer , Etobicoke , ON , Canada	9106
⁄ kg i.p.	9106
⁄ kg	9106
Bayer , Etobicoke , ON , Canada	9117
a laminectomy	9148
the left side	9179
the fourth and fifth cervical segments	9203
the fourth	9203
fifth cervical segments	9218
The dura	9243
microscissors	9265
the spinal cord	9289
the dorsolateral funiculus	9309
the rubrospinal tract	9346
20 s with custom-designed fine surgical forceps at a depth of 2 mm	9384
20 s	9384
custom-designed fine surgical forceps at a depth of 2 mm	9394
custom-designed fine surgical forceps	9394
a depth of 2 mm	9435
a depth	9435
2 mm	9446
Ramer	9491
et al. , 2004a ; Richter et al. , 2005	9497
et al.	9497
2004a ; Richter et al.	9505
2004a	9505
Richter et al.	9512
Richter	9512
et al.	9520
2005	9528
The distal blades of # 5 Dumont forceps	9535
The distal blades	9535
# 5 Dumont forceps	9556
a width of 0.2 mm	9592
a width	9592
0.2 mm	9603
the length of exactly 2 mm	9614
the length	9614
exactly 2 mm	9628
a reproducible insertion of a fine tip	9651
a reproducible insertion	9651
a fine tip	9679
the desired depth of 2 mm -LRB- see also Plunet et al. , 2008 -RRB-	9693
the desired depth	9693
2 mm -LRB- see also Plunet et al. , 2008 -RRB-	9714
2 mm	9714
Plunet	9729
et al. , 2008	9736
et al.	9736
2008	9744
Cell transplantation LP-OECs	9751
the spinal cord	9803
Ramer	9844
et al. , 2004a ; Richter et al. , 2005	9850
et al.	9850
2004a ; Richter et al.	9858
2004a	9858
Richter et al.	9865
Richter	9865
et al.	9873
2005	9881
LP-OEC slurries in DMEM ⁄ F-12	9888
LP-OEC slurries	9888
DMEM ⁄ F-12	9907
the pulled glass pipette with a diameter of 60	9934
the pulled glass pipette	9934
a diameter of 60	9964
a diameter	9964
60	9978
80 µm attached to a Hamilton syringe	9981
80 µm	9981
a Hamilton syringe	9999
OECs	10019
1 mm rostral and caudal	10059
1 mm rostral	10059
caudal	10076
the lesion site	10086
the suspension	10112
these two points	10143
A total of 1.5 µL of cell slurry	10161
A total	10161
1.5 µL of cell slurry	10172
1.5 µL	10172
cell slurry	10182
each rat	10216
a total of 150 000	10234
a total	10234
150 000	10245
180 000 cells	10253
Control animals	10268
the same volume of DMEM ⁄ F-12	10293
the same volume	10293
DMEM ⁄ F-12	10312
the same sites	10335
the same rate	10357
The glass pipette	10372
place for 5 min	10402
place	10402
5 min	10412
each injection	10424
cells	10454
the spinal cord	10472
the syringe	10516
injection	10535
the pipette	10546
the muscle	10582
the skin	10610
wound clips	10631
Cell body treatment BDNF or vehicle	10644
Cell body treatment BDNF	10644
vehicle	10672
2 weeks	10696
a cannula	10708
the vicinity of the red nucleus	10742
the vicinity	10742
the red nucleus	10758
Kobayashi	10800
et al. , 1997 ; Kwon et al. , 2002	10810
et al.	10810
1997 ; Kwon et al.	10818
1997	10818
Kwon et al.	10824
Kwon	10824
et al.	10829
2002	10837
brief	10847
cell transplantation -LRB- while the rats were still anesthetized as above -RRB-	10860
cell transplantation	10860
the rats	10888
a 28	10932
gage cannula	10938
silastic tubing	10964
an osmotic minipump	10983
Alzet no. 2002 , 0.5 µL ⁄ h ; Alzet , Palo Alto , CA , USA	11004
Alzet no. 2002	11004
Alzet	11004
2002	11014
0.5 µL ⁄ h ; Alzet , Palo Alto	11020
0.5 µL ⁄ h	11020
0.5 µL	11020
⁄ h	11027
Alzet , Palo Alto	11032
Alzet	11032
Palo Alto	11039
CA , USA	11050
CA	11050
USA	11054
6.3 mm posterior to Bregma	11088
6.3 mm posterior	11088
Bregma	11108
1.7 mm lateral -LRB- right -RRB- of midline	11116
1.7 mm lateral -LRB- right -RRB-	11116
1.7 mm lateral	11116
right	11132
midline	11142
6.5 mm	11154
the dura	11171
Animals treated with BDNF	11181
Animals	11181
BDNF	11202
0.5 lg ⁄ µL	11216
⁄ h	11228
BDNF	11235
gift from Regeneron Pharmaceuticals , Tarrytown , NY ,	11241
gift	11241
Regeneron Pharmaceuticals , Tarrytown , NY ,	11251
USA	11293
a vehicle solution of 20 mm sterile PBS	11301
a vehicle solution	11301
20 mm sterile PBS	11323
20 mm	11323
100 U of P ⁄ S and 0.5 % rat serum albumin -LRB- Sigma-Aldrich ; no	11342
100 U of P ⁄ S	11342
100 U	11342
P ⁄ S	11351
0.5 % rat serum albumin -LRB- Sigma-Aldrich ; no	11361
0.5 %	11361
rat serum albumin -LRB- Sigma-Aldrich ; no	11366
rat serum albumin	11366
Sigma-Aldrich ; no	11385
Sigma-Aldrich	11385
no	11400
A-6272	11404
Animals treated with vehicle	11413
Animals	11413
vehicle	11434
the vehicle solution	11451
insertion	11485
the cannula and insertion of the osmotic minipump under the skin of the neck	11498
the cannula and insertion	11498
the osmotic minipump under the skin of the neck	11527
the osmotic minipump	11527
the skin of the neck	11554
the skin	11554
the neck	11566
the skin	11576
wound clips	11601
Fig. 1 and Table 1 for the experimental design and more details	11618
Fig. 1	11618
Table 1 for the experimental design and more details	11629
Table 1	11629
the experimental design and more details	11641
the experimental design	11641
more details	11669
Behavioral testing Cylinder test Forelimb usage	11683
Behavioral testing Cylinder	11683
test Forelimb usage	11711
a clear Plexiglas cylinder -LRB- 20 cm in diameter and 30 cm high -RRB-	11749
a clear Plexiglas cylinder	11749
20 cm in diameter and 30 cm	11777
20 cm	11777
diameter and 30 cm	11786
diameter	11786
30 cm	11799
5 min -LRB- Liu et al. , 1999 -RRB-	11815
5 min	11815
Liu	11822
et al. , 1999	11826
et al.	11826
1999	11834
The cylinder	11841
rats	11865
their forelimbs	11877
vertical exploration	11897
A mirror	11919
the cylinder	11946
scoring of movements from all viewpoints	11969
scoring	11969
movements from all viewpoints	11980
movements	11980
all viewpoints	11995
The behavior	12011
frame	12035
frame	12044
a later time-point	12053
a blinded rater	12075
Forelimb use	12092
independent use of the left injured forelimb	12119
independent use	12119
the left injured forelimb	12138
independent use of the right forelimb	12165
independent use	12165
the right forelimb	12184
concomitant use of both forelimbs	12207
concomitant use	12207
both forelimbs	12226
the wall of the cylinder	12256
the wall	12256
the cylinder	12268
a full rear	12288
a more accurate use of the left forelimb	12312
a more accurate use	12312
the left forelimb	12335
the score	12354
a percentage use	12381
the ` left and both ' forelimbs	12401
the total number of left , right and both forelimb use	12443
the total number of left	12443
the total number	12443
left	12463
right	12469
both forelimb use	12479
Food-pellet reaching task The food-pellet reaching task used	12498
Food-pellet	12498
task	12519
The food-pellet	12524
task used	12549
task	12549
Whishaw	12575
et al. -LRB- 1993 -RRB-	12583
et al.	12583
1993	12591
Chan et al. , 2005	12627
Chan	12627
et al.	12632
2005	12640
brief	12650
the rats	12657
injury	12686
a 1-cm opening a food pellet placed in a dimple 2 cm away	12710
a 1-cm	12710
a food pellet placed in a dimple 2 cm away	12725
a food pellet	12725
a dimple 2 cm away	12749
a dimple	12749
2 cm	12758
The behavior	12769
a 10-point scale	12796
the execution of sequential aspects	12825
the execution	12825
sequential aspects	12842
score 3	12875
score 5	12895
score 7	12920
a food pellet	12929
details , see Chan et al. , 2005	12948
details	12948
Chan	12961
et al. , 2005	12966
et al.	12966
2005	12974
Sensory tests The sensory testing	12981
Sensory tests	12981
The sensory testing	12995
Ramer et al. , 2004b	13044
Ramer	13044
et al.	13050
2004b	13058
The thermal threshold of forepaws	13066
The thermal threshold	13066
forepaws	13091
the plantar tester -LRB- Ugo Basile , Italy -RRB-	13122
the plantar tester	13122
Ugo Basile	13142
Italy	13154
Rats	13162
a designed cage in a glass floor over a moveable infrared generator	13182
a designed cage	13182
a glass floor over a moveable infrared generator	13201
a glass floor	13201
a moveable infrared generator	13220
The infrared source	13251
The	13251
source	13264
the center of the palmar forepaw	13292
the center	13292
the palmar forepaw	13306
The time from stimulus onset to withdrawal	13326
The time	13326
stimulus onset to withdrawal	13340
stimulus onset	13340
withdrawal	13358
both forepaws	13386
Mechanical threshold of forepaws	13401
Mechanical threshold	13401
forepaws	13425
the plantar aesthesiometer -LRB- Ugo Basile , Italy -RRB-	13458
the plantar aesthesiometer	13458
Ugo Basile	13486
Italy	13498
Rats	13506
a raised cage with a wire mesh floor over the stimulator unit	13526
a raised cage	13526
a wire mesh floor over the stimulator unit	13545
a wire mesh floor	13545
the stimulator unit	13568
The vertical metal filament	13589
the center of the palmar surface of the forepaw	13632
the center	13632
the palmar surface of the forepaw	13646
the palmar surface	13646
the forepaw	13668
force	13692
1 to 50 g	13717
7	13732
s. Force and latency at withdrawal	13734
s. Force	13734
latency at withdrawal	13747
latency	13747
withdrawal	13758
both forepaws	13787
both sensory tests	13806
rats	13826
weekly two -- three times for each paw for 2 -- 3 weeks	13843
weekly two -- three times for each paw for 2 --	13843
weekly two	13843
three times for each paw for 2	13854
three times	13854
each paw for 2	13870
each paw	13870
2	13883
3 weeks	13885
injury	13900
a control baseline	13917
4 weeks	13945
injury and treatment	13959
Baseline behavior	13981
surgery	14019
all animals	14032
4 weeks	14067
injury and treatment	14081
rats	14112
the food-pellet	14128
task	14153
any influences	14173
other behavioral tests	14191
all rats	14215
a week the night	14241
a week	14241
the night	14248
the testing day	14268
rubrospinal axons and immunocytochemistry Anterograde labeling	14297
rubrospinal axons	14363
Five weeks	14381
spinal cord injury and treatment	14398
spinal cord injury	14398
treatment	14421
rats	14432
a mixture	14460
ketamine hydrochloride	14473
70 mg ⁄ kg , i.p. ; Bimeda-MTC , Cambridge , ON , Canada	14497
70 mg	14497
⁄ kg , i.p. ; Bimeda-MTC , Cambridge , ON , Canada	14503
⁄ kg , i.p.	14503
⁄ kg	14503
Bimeda-MTC , Cambridge , ON , Canada	14515
xylazine hydrochloride	14554
10 mg ⁄ kg i.p. ; Bayer , Etobicoke , ON , Canada	14578
10 mg	14578
⁄ kg i.p. ; Bayer , Etobicoke , ON , Canada	14584
⁄ kg i.p.	14584
⁄ kg	14584
Bayer , Etobicoke , ON , Canada	14595
placed in a Kopf stereotaxic frame	14630
a Kopf	14640
dextran amine	14679
BDA ; 10 000 kDa molecular mass	14694
BDA	14694
10 000 kDa molecular mass	14699
10 000	14699
kDa molecular mass	14706
10 % in sterile water	14726
10 %	14726
sterile water	14733
Molecular Probes	14748
Eugene	14766
OR , USA	14774
OR	14774
USA	14778
the red nucleus at a rate of 30 nL	14817
the red nucleus	14817
a rate of 30 nL	14836
a rate	14836
30 nL	14846
⁄ min	14852
a pulled glass pipette -LRB- diameter of 20 µm -RRB- glued to a Hamilton syringe	14867
a pulled glass pipette -LRB- diameter of 20 µm -RRB-	14867
a pulled glass pipette	14867
diameter of 20 µm	14891
diameter	14891
20 µm	14903
a Hamilton syringe	14919
Coordinates	14939
6.1 mm posterior	14956
Bregma , 0.7 mm lateral -LRB- right -RRB- of midline	14976
Bregma	14976
0.7 mm lateral -LRB- right -RRB- of midline	14984
0.7 mm lateral -LRB- right -RRB-	14984
0.7 mm lateral	14984
right	15000
midline	15010
7 mm	15022
the dura	15037
The pipette	15047
place for 10 min	15071
place	15071
10 min	15081
injection	15094
BDA	15119
the syringe	15146
Immunocytochemistry	15159
Six weeks	15179
injury and treatment	15195
rats	15217
a lethal dose of chloral hydrate	15245
a lethal dose	15245
chloral hydrate	15262
100 mg ⁄ kg , i.p. ; BDH Chemicals , Toronto , ON , Canada	15279
100 mg	15279
⁄ kg , i.p. ; BDH Chemicals , Toronto , ON , Canada	15286
⁄ kg , i.p.	15286
⁄ kg	15286
BDH Chemicals , Toronto , ON , Canada	15298
BDH Chemicals	15298
Toronto , ON , Canada	15313
PBS	15367
phosphate-buffered , 4 % paraformaldehyde -LRB- pH 7.4 -RRB-	15383
phosphate-buffered , 4 % paraformaldehyde	15383
pH 7.4	15424
The midbrain , cerebellum and cervical spinal cords	15433
The midbrain	15433
cerebellum	15447
cervical spinal cords	15462
4 % paraformaldehyde	15513
24 % sucrose in 0.1 m phosphate buffer over 2 -- 3 days	15561
24 % sucrose in 0.1 m phosphate buffer over 2	15561
24 % sucrose	15561
0.1 m phosphate buffer over 2	15576
0.1 m phosphate buffer	15576
2	15604
3 days	15606
isopentane over dry ice	15628
isopentane	15628
dry ice	15644
Spinal cords	15653
20-µm sections	15680
a cryostat	15698
80 °C	15724
Cervical segments C2 and C7	15730
Cervical segments C2	15730
C7	15755
20-µm sections in the coronal plane	15772
20-µm sections	15772
the coronal plane	15790
Cervical segments from C3 to C6	15809
Cervical segments	15809
C3 to C6	15832
C3	15832
C6	15838
20-µm longitudinal sections in the horizontal plane	15855
20-µm longitudinal sections	15855
the horizontal plane	15886
frozen sections	15923
a slide warmer for 30 min	15954
a slide warmer	15954
30 min	15973
10 mm PBS three times for 5 min	15995
10 mm PBS	15995
three times	16005
5 min	16021
10 % normal donkey serum -LRB- in 0.1 % Triton X-100 -RRB-	16047
10 % normal donkey serum	16047
10 %	16047
in 0.1 % Triton X-100	16072
0.1 %	16075
Triton X-100	16080
Triton	16080
X-100	16087
30 min	16098
nonspecific binding	16116
The following primary antibodies	16137
chicken anti-GFP -LRB- anti-GFP , 1 : 1000 ; Chemicon -RRB-	16181
chicken anti-GFP	16181
anti-GFP , 1	16199
anti-GFP	16199
1	16209
1000 ; Chemicon	16213
1000	16213
Chemicon	16219
rabbit anti-GFP -LRB- anti-GFP , 1 : 1000 ; Chemicon -RRB-	16230
rabbit anti-GFP	16230
anti-GFP , 1	16247
anti-GFP	16247
1	16257
1000 ; Chemicon	16261
1000	16261
Chemicon	16267
mouse anti-GFAP -LRB- anti-GFAP , 1 : 400 ; Sigma -RRB-	16278
mouse anti-GFAP	16278
anti-GFAP , 1	16295
anti-GFAP	16295
1	16306
400 ; Sigma	16310
400	16310
Sigma	16315
mouse anti-neurofilament 200 -LRB- anti-NF , 1 : 400 ; Sigma -RRB-	16323
mouse anti-neurofilament 200	16323
mouse anti-neurofilament	16323
200	16348
anti-NF , 1	16353
anti-NF	16353
1	16362
400 ; Sigma	16366
400	16366
Sigma	16371
mouse anti-beta-III-tubulin -LRB- anti-tub , 1 : 400 ; Sigma -RRB-	16379
mouse anti-beta-III-tubulin	16379
anti-tub , 1	16408
anti-tub	16408
1	16418
400 ; Sigma	16422
400	16422
Sigma	16427
rabbit anti-serotonin transporter -LRB- anti-SERT , 1 : 500 ; ImmunoStar -RRB-	16435
rabbit anti-serotonin transporter	16435
anti-SERT , 1	16470
anti-SERT	16470
1	16481
500 ; ImmunoStar	16485
500	16485
ImmunoStar	16490
sheep anti-tyrosine hydroxylase -LRB- anti-TH , 1 : 200 ; Chemicon -RRB-	16503
sheep anti-tyrosine hydroxylase	16503
anti-TH , 1	16536
anti-TH	16536
1	16545
200 ; Chemicon	16549
200	16549
Chemicon	16554
rabbit anti-calcitonin gene-related peptide	16565
anti-CGRP , 1	16610
anti-CGRP	16610
1	16621
500 ; Sigma	16625
500	16625
Sigma	16630
chicken anti-P0 -LRB- anti-P0 , 1 : 100 ; AvesLabs -RRB-	16638
chicken anti-P0	16638
anti-P0 , 1	16655
anti-P0	16655
1	16664
100 ; AvesLabs	16668
100	16668
AvesLabs	16673
chicken anti-myelin basic protein	16687
chicken	16687
anti-myelin basic protein	16695
anti-MBP	16722
1	16732
100 ; AvesLabs	16736
100	16736
AvesLabs	16741
All primary antibodies	16752
24 h at room temperature	16792
24 h	16792
room temperature	16800
Secondary antibodies -LRB- 1 : 200 , Jackson -RRB-	16818
Secondary antibodies	16818
1 : 200 , Jackson	16840
1 : 200	16840
Jackson	16849
donkey	16868
Alexa 350 , Alexa 488 and Cy3	16890
Alexa 350	16890
Alexa 488	16901
Cy3	16915
2	16941
3 h at room temperature	16943
3 h	16943
room temperature	16950
BDA	16968
Cy3	16996
AMCA-conjugated streptavidin -LRB- 1 : 400 , Jackson -RRB- applied for 2	17004
AMCA-conjugated streptavidin -LRB- 1 : 400 , Jackson -RRB-	17004
AMCA-conjugated streptavidin	17004
1 : 400 , Jackson	17034
1 : 400	17034
Jackson	17043
2	17064
3 h at room temperature	17066
3 h	17066
room temperature	17073
Sections	17091
glycerol mounting liquid -LRB- Sigma -RRB-	17121
glycerol mounting liquid	17121
Sigma	17147
Image analysis and quantification Images	17155
an Axioplan 2 microscope -LRB- Zeiss , Jena , Germany -RRB-	17225
an Axioplan 2 microscope	17225
Zeiss	17251
Jena	17258
Germany	17264
a digital camera -LRB- QImaging , Burnaby , BC , Canada -RRB-	17274
a digital camera	17274
QImaging	17292
Burnaby	17302
BC , Canada	17311
Northern Eclipse software -LRB- Empix Imaging , Mississauga , ON , Canada -RRB-	17327
Northern Eclipse software	17327
Empix Imaging	17354
Mississauga	17369
ON , Canada	17382
Digital images	17395
Photoshop 7.0	17439
Adobe Systems	17454
San Jose	17469
CA , USA	17479
SigmaScan Pro -LRB- SPSS , Chicago , IL , USA -RRB-	17489
SigmaScan	17489
Pro -LRB- SPSS , Chicago , IL , USA -RRB-	17499
Pro	17499
SPSS , Chicago	17504
IL	17519
USA	17523
Matlab 6.5 -LRB- The MathWorks , Natick , MA , USA -RRB- softwares	17532
Matlab 6.5	17532
The MathWorks	17544
Natick	17559
MA , USA	17567
softwares	17576
The number of rubrospinal axons	17587
The number	17587
rubrospinal axons	17601
each animal	17638
the number of BDA-traced axons	17663
the number	17663
BDA-traced axons	17677
three cross-sections at C2	17697
three cross-sections	17697
C2	17721
Rubrospinal regeneration	17725
the presence	17780
traced axons	17796
the spinal cord	17820
every other 20 µm in longitudinal -LRB- horizontal -RRB- sections	17836
every other 20 µm	17836
longitudinal -LRB- horizontal -RRB- sections	17857
we	17896
any evidence for axonal regeneration	17912
any evidence	17912
axonal regeneration	17929
we	17950
each animal	17977
the distance	17989
the terminal ends	18010
the most caudal five rubrospinal axon tips and the lesion epicenter	18031
five rubrospinal axon tips and the lesion epicenter	18047
five rubrospinal axon tips	18047
the lesion epicenter	18078
the three best	18105
longitudinal sections of the rubrospinal tract	18127
longitudinal sections	18127
the rubrospinal tract	18152
the dorsolateral funiculus	18177
This	18205
a measure of rubrospinal axon retraction	18221
a measure	18221
rubrospinal axon retraction	18234
the injury	18297
The efficacy of the axonal tracing	18309
The efficacy	18309
the axonal tracing	18325
the axonal	18325
the number	18370
rubrospinal axons measured on three different cervical coronal sections at C2	18384
rubrospinal axons	18384
three different cervical coronal sections	18414
C2	18459
Lesion area and cavity size	18463
Lesion area	18463
cavity size	18479
each animal	18511
the lesion area	18536
GFAP immunoreactivity	18563
three	18588
levels	18602
the dorsal root entry zone and the central canal	18637
the dorsal root entry zone	18637
the central canal	18668
the total pixels in this area	18703
the total pixels	18703
this area	18723
GFAP immunoreactivity	18734
the intensity	18783
a 50-µm width area	18804
the lesion site	18838
these former three longitudinal sections	18857
the analogous area	18916
the contralateral uninjured side of the spinal cord	18938
the contralateral uninjured side	18938
the spinal cord	18974
Immunopositive cellular or axonal density measurements	18991
axonal density	19018
Ramer	19064
et al. -LRB- 2004b -RRB-	19070
et al.	19070
2004b	19078
brief	19089
images	19096
three sections -LRB- per animal -RRB-	19122
three sections	19122
animal	19142
the horizontal plane	19153
the dorsal root entry zone and the central canal	19202
the dorsal root entry zone	19202
the central canal	19233
A Laplace transformation	19252
the edges of the immunoreactive axonal and cellular profiles	19305
the edges	19305
the immunoreactive axonal and cellular profiles	19318
This step	19367
fluctuations in the brightness of the immunofluorescent signal	19393
fluctuations	19393
the brightness of the immunofluorescent signal	19409
the brightness	19409
the immunofluorescent signal	19427
a threshold -LRB- using the same throughout the experiment -RRB-	19470
a threshold	19470
the same	19489
the experiment	19509
an overlay	19541
the axonal profiles	19593
The pixel area occupied by the thresholded axonal profiles	19614
The pixel area	19614
the thresholded axonal profiles	19641
the area -LRB- pixel number -RRB- of the selected measurement window	19688
the area -LRB- pixel number -RRB-	19688
the area	19688
pixel number	19698
the selected measurement window	19715
axonal density values -LRB- ratios -RRB-	19759
axonal density values	19759
ratios	19782
The same procedure	19791
the GFP-positive transplanted cells	19825
a measure	19871
their density	19884
the density of their cytoplasmic and nuclear borders	19917
the density	19917
their cytoplasmic and nuclear borders	19932
their cytoplasmic	19932
nuclear borders	19954
the measurement window	19978
Averaged axonal and cell density measurements from each treatment group	20002
Averaged axonal and cell density measurements	20002
each treatment group	20053
a function of the distance from the lesion epicenter	20104
a function	20104
the distance from the lesion epicenter	20118
the distance	20118
the lesion epicenter	20136
Statistical analysis	20158
A two-way repeated anova	20179
interactions between treatment and distance	20223
interactions	20223
treatment and distance	20244
the axonal and cellular density	20271
interactions between treatment and time course	20318
interactions	20318
treatment and time course	20339
the behavioral outcomes	20369
A one-way anova	20394
differences in the axonal or cellular density	20429
differences	20429
the axonal or cellular density	20444
each given distance	20478
differences in behavioral outcome measurements	20512
differences	20512
behavioral outcome measurements	20527
each time-point	20562
A one-way anova was used to detect differences between	20579
A one-way anova	20579
differences	20614
density measurements	20643
rubrospinal axon retraction and lesion area measurements	20675
the treatment	20745
The data	20760
further analysed using the post hoc Tukey -- Kramer test	20774
further	20774
the post hoc Tukey	20797
the post	20797
Kramer test	20816
the cases where the variables did not fit a normal distribution	20832
the cases	20832
the variables	20848
a normal distribution	20874
the non-parametric Kruskal -- Wallis	20897
the non-parametric Kruskal	20897
Wallis	20925
sum test	20939
a chi-square test	20970
all cases	20992
significance	21003
P	21029
Results Table 1 .	21040
Results	21040
Table 1	21048
Number of animals	21057
Number	21057
animals	21067
histological and behavioral quantifications Fig. 1	21084
histological and behavioral quantifications	21084
Fig. 1	21129
Experimental design .	21137
The dorsolateral funiculus including the rubrospinal tract	21158
The dorsolateral funiculus	21158
the rubrospinal tract	21195
C4 -- C5	21235
C4	21235
C5	21238
Olfactory ensheathing cells -LRB- OECs -RRB-	21242
Olfactory ensheathing cells	21242
OECs	21271
the lamina-propria -LRB- LP -RRB-	21290
neo-natal mouse	21317
GFP	21344
1 mm	21386
the lesion epicenter	21395
DMEM	21417
control	21438
the same locations	21451
combination with this spinal bridge	21474
combination	21474
this spinal bridge	21491
rubrospinal neurons	21511
brain-derived neurotrophic factor	21549
BDNF	21584
vehicle	21593
control	21605
2 weeks via a cannula inserted into the vicinity of the red nucleus	21618
2 weeks	21618
a cannula inserted into the vicinity of the red nucleus	21630
a cannula	21630
the vicinity of the red nucleus	21654
the vicinity	21654
the red nucleus	21670
Fig. 2 .	21688
Fig.	21688
2	21693
Olfactory ensheathing cells -LRB- OECs -RRB-	21696
Olfactory ensheathing cells	21696
OECs	21725
the injured spinal cord	21738
rubrospinal axons	21767
-LRB- A -RRB- Camera lucida of rubrospinal axons .	21804
-LRB- A -RRB-	21804
Camera lucida of rubrospinal axons	21808
Camera lucida	21808
rubrospinal axons	21825
Representative	21844
longitudinal spinal cord sections	21859
the dorsolateral funiculus level for different treatments and their combinations	21896
the dorsolateral funiculus level	21896
different treatments and their combinations	21933
different treatments	21933
their combinations	21958
rubrospinal axons	21983
the white matter	22011
the rostral OECs graft -LRB- light gray area -RRB-	22042
the rostral OECs graft	22042
light gray area	22066
the edge of the OEC	22096
the edge	22096
the OEC	22108
transplants bridging the lesion site	22116
transplants	22116
the lesion site	22137
Rubrospinal branching within the gray matter -LRB- dark gray area -RRB-	22154
Rubrospinal	22154
the gray matter -LRB- dark gray area -RRB-	22183
the gray matter	22183
dark gray area	22200
B and C	22237
B	22237
C	22243
Horizontal sections of the cervical spinal cord injury site	22246
Horizontal sections	22246
the cervical spinal cord injury site	22269
astrocytes -LSB- glial fibrillary acidic protein -LRB- GFAP -RRB-	22324
astrocytes -LSB- glial fibrillary acidic protein	22324
astrocytes -LSB-	22324
GFAP	22369
blue -RSB-	22378
LP-OECs -LSB- green fluorescent protein -LRB- GFP -RRB-	22385
LP-OECs -LSB- green fluorescent protein	22385
GFP	22421
green -RSB- and rubrospinal axons	22429
biotinylated dextran amine -LRB- BDA -RRB- in red -RSB-	22459
biotinylated dextran amine	22459
BDA	22487
red -RSB-	22495
-LRB- B -RRB- Vehicle	22501
-LRB- B -RRB-	22501
Vehicle	22505
OEC-treated rats	22514
vehicle	22547
the rubrospinal neuron level and OECs	22558
the rubrospinal neuron level	22558
OECs	22591
the spinal cord level	22599
-LRB- C -RRB- Brain-derived neurotrophic factor -LRB- BDNF -RRB-	22622
-LRB- C -RRB- Brain-derived neurotrophic factor	22622
-LRB- C -RRB-	22622
Brain-derived neurotrophic factor	22626
BDNF	22661
rats	22678
Neither treatment alone or in combination	22684
Neither treatment	22684
combination	22714
regeneration of rubrospinal axons	22735
regeneration	22735
rubrospinal axons	22751
The white asterisks in B and C	22770
The white asterisks	22770
B and C	22793
the lesion epicenters	22810
Fig. 3 .	22834
Fig.	22834
3	22839
LP-olfactory ensheathing cells -LRB- OECs -RRB-	22842
LP-olfactory ensheathing cells	22842
OECs	22874
the cell body treatment	22896
lesion area , cavity formation and glial scar formation	22930
lesion area	22930
cavity formation	22943
glial scar formation	22964
-LRB- A -RRB- Mean lesion area -LRB- GFAP-negative area -RRB- .	22986
-LRB- A -RRB-	22986
Mean lesion area -LRB- GFAP-negative area -RRB-	22990
Mean lesion area	22990
GFAP-negative area	23008
-LRB- B -RRB-	23029
Mean cavitation area -LRB- background area within the lesion site -RRB-	23033
Mean cavitation area	23033
background area within the lesion site	23055
background area	23055
the lesion site	23078
-LRB- C -RRB- Percentage of lesion site	23096
-LRB- C -RRB-	23096
lesion site	23114
cavity formation	23138
-LRB- D -RRB- GFAP immunodensity along the lesion site	23156
-LRB- D -RRB- GFAP immunodensity	23156
-LRB- D -RRB-	23156
GFAP immunodensity	23160
the lesion site	23185
the contralateral non-injured side	23215
Error bars	23251
SEM -LSB- Kruskal -- Wallis , P < 0.01 : *	23271
SEM -LSB- Kruskal -- Wallis , P < 0.01 :	23271
SEM	23271
Kruskal -- Wallis , P < 0.01 :	23276
Kruskal	23276
Wallis , P < 0.01	23284
Wallis	23284
P < 0.01	23292
P <	23292
P	23292
0.01	23296
Veh -- DMEM	23317
Veh	23317
DMEM	23321
brain-derived neurotrophic factor -LRB- BDNF -RRB- -- DMEM and Veh -- DMEM -RSB-	23343
brain-derived neurotrophic factor -LRB- BDNF -RRB-	23343
brain-derived neurotrophic factor	23343
BDNF	23378
DMEM and Veh -- DMEM	23384
DMEM and Veh	23384
DMEM	23397
Fig. 4 .	23405
Fig.	23405
4	23410
LP-olfactory ensheathing cells	23413
OECs	23445
survival	23451
the cell body treatment	23479
OEC density	23504
a function	23519
the distance	23533
the lesion epicenter from brain-derived neurotrophic factor -LRB- BDNF -RRB-	23551
the lesion epicenter	23551
brain-derived neurotrophic factor -LRB- BDNF -RRB-	23577
brain-derived neurotrophic factor	23577
BDNF	23612
OECs - and Veh -- OECs-treated rats	23618
OECs	23618
Veh	23628
OECs-treated rats	23633
Error bars	23652
SEM	23672
two-way repeated-measures	23677
anova	23703
no treatment · distance interaction	23718
P = 0.985	23755
P	23755
0.985	23759
a treatment effect , P = 0.959	23769
a treatment effect	23769
P = 0.959	23789
P	23789
0.959	23793
GFP , green fluorescent protein .	23801
GFP	23801
green fluorescent protein	23806
Fig. 5 .	23834
Fig.	23834
5	23839
three treatments , olfactory ensheathing cell -LRB- OEC -RRB- transplantation ,	23846
three treatments	23846
olfactory ensheathing cell -LRB- OEC -RRB- transplantation	23864
olfactory ensheathing cell	23864
OEC	23892
transplantation	23897
brain-derived neurotrophic factor -LRB- BDNF -RRB-	23939
brain-derived neurotrophic factor	23939
BDNF	23974
their combination	23991
retraction of rubrospinal axons	24019
retraction	24019
rubrospinal axons	24033
lesion epicenter	24056
-LRB- A -RRB-	24074
Distance	24078
rubrospinal axonal terminals	24090
the lesion epicenter as a function of different treatments	24124
the lesion epicenter	24124
a function of different treatments	24148
a function	24148
different treatments	24162
-LRB- B -RRB-	24184
Number of rubrospinal axons at the cervical segment C2 rostral to the lesion	24188
Number	24188
rubrospinal axons at the cervical segment C2 rostral to the lesion	24198
rubrospinal axons	24198
the cervical segment C2 rostral to the lesion	24219
the cervical segment C2 rostral	24219
the lesion	24254
Error bars	24266
SEM	24286
oneway anova , P	24293
oneway	24293
anova , P	24300
anova	24300
P	24307
< 0.05	24309
<	24309
0.05	24311
the control group Veh	24331
DMEM	24353
the combinatorial therapy BDNF -- OECs	24379
the combinatorial therapy BDNF	24379
OECs	24410
regeneration	24431
it	24445
the number of axons	24458
the number	24458
axons	24472
C2	24481
the retraction of rubrospinal terminals	24498
the retraction	24498
rubrospinal terminals	24516
the lesion epicenter	24543
Fig. 6 .	24566
Fig.	24566
6	24571
Olfactory ensheathing cells -LRB- OECs -RRB-	24574
Olfactory ensheathing cells	24574
OECs	24603
regeneration of unidentified thin and thick axons	24618
regeneration	24618
unidentified thin and thick axons	24634
the cell body treatment	24684
Axonal density of thin and thick axons	24709
Axonal density	24709
thin and thick axons	24727
neurofilament -LRB- NF -RRB-	24749
neurofilament	24749
NF	24764
beta-III-tubulin -LRB- tub -RRB- - positive structures , respectively -RSB-	24777
beta-III-tubulin	24777
tub	24795
positive structures , respectively	24800
positive structures	24800
the OECs graft	24846
the cell body treatment	24874
BDNF -- OEC treatment	24918
BDNF	24918
OEC treatment	24923
the axonal density	24947
no significant differences	24976
both groups -LRB- anova , P = 0.437 -RRB-	25025
both groups	25025
anova , P = 0.437	25038
anova	25038
P = 0.437	25045
P	25045
0.437	25049
Error bars	25057
SEM	25077
Fig. 7 .	25083
Fig.	25083
7	25088
Absence	25091
regenerative sprouting of supraspinal axons and peripheral afferents into	25102
regenerative	25102
supraspinal axons and peripheral afferents	25128
supraspinal axons	25128
peripheral afferents	25150
LP-olfactory ensheathing cells -LRB- OECs -RRB-	25186
LP-olfactory ensheathing cells	25186
OECs	25218
small diameter peptidergic fibers	25232
OECs alone -LRB- left column -RRB-	25267
OECs alone	25267
OECs	25267
column	25284
combination	25298
brain-derived neurotrophic factor -LRB- BDNF ; middle column -RRB-	25315
brain-derived neurotrophic factor	25315
BDNF ; middle column	25350
BDNF	25350
middle column	25356
immunoreactivity of marker of serotoninergic re-uptake vesicles -LRB- SERT -	25381
immunoreactivity	25381
marker of serotoninergic re-uptake vesicles -LRB- SERT -	25401
marker	25401
serotoninergic re-uptake vesicles -LRB- SERT -	25411
serotoninergic re-uptake vesicles	25411
SERT	25446
A -- C	25453
A	25453
C	25455
tyrosine hydroxylase -LRB- TH - ; D -- F ; marker of noradrenergic fibers -RRB-	25462
tyrosine hydroxylase	25462
TH	25484
; D -- F ; marker	25487
D -- F	25489
D	25489
F	25491
noradrenergic fibers	25504
positive fibers rostral	25526
the lesion site	25553
poor or no regeneration of these fibers	25583
poor or no regeneration	25583
these fibers	25610
the OECs graft	25628
OECs	25655
immunoreactivity of substance-P -LRB- Sub-P -RRB-	25670
immunoreactivity	25670
substance-P -LRB- Sub-P -RRB-	25690
substance-P	25690
Sub-P	25703
positive fibers -LRB- G -- I ; marker of peripheral afferent terminals -RRB-	25710
positive fibers	25710
G	25727
I ; marker of peripheral afferent terminals	25729
I	25729
marker of peripheral afferent terminals	25732
marker	25732
peripheral afferent terminals	25742
the lesion site	25783
the OECs graft	25821
Only calcitonin gene-related peptide -LRB- CGRP -RRB-	25837
Only calcitonin	25837
gene-related peptide -LRB- CGRP -RRB-	25853
gene-related peptide	25853
CGRP	25875
positive fibers	25881
J	25898
L ; marker of peptidergic small diameter peripheral afferent terminals	25900
L	25900
marker of peptidergic small diameter peripheral afferent terminals	25903
marker	25903
peptidergic small diameter peripheral afferent terminals	25913
the engrafted OECs	25981
the	25981
OECs	25995
Right column	26001
axonal density of SERT - , TH - , Sub-P	26015
axonal density of SERT - , TH -	26015
axonal density	26015
SERT	26033
TH	26040
Sub-P	26045
CGRP-positive fibers	26056
a function of the distance from the lesion epicenter according to the treatment	26080
a function	26080
the distance from the lesion epicenter according to the treatment	26094
the distance	26094
the lesion epicenter according to the treatment	26112
the lesion epicenter	26112
the treatment	26146
significant increases	26166
CGRP axonal density in BDNF -- OEC - and Veh	26191
CGRP axonal density in BDNF -- OEC	26191
CGRP axonal density	26191
BDNF	26214
Veh	26228
rats in comparison with BDNF -- DMEM	26245
rats in comparison with BDNF --	26245
rats	26245
comparison with BDNF --	26253
comparison	26253
BDNF	26269
light gray line	26288
Veh -- DMEM - treated ones	26309
Veh	26309
treated ones	26320
Error bars	26334
SEM	26354
Two-way repeated-measures anova -LRB- P < 0.05 -RRB-	26359
Two-way repeated-measures anova	26359
P < 0.05	26392
P	26392
< 0.05	26394
<	26394
0.05	26396
a time · distance interaction	26411
SERT , TH and CGRP fibers	26445
SERT	26445
TH	26451
CGRP fibers	26458
One-way anova	26471
P	26486
<	26488
0.05	26490
-LRB- BDNF -- OECs and Veh -- OECs -RRB-	26497
BDNF	26498
OECs and Veh -- OECs	26503
OECs	26503
Veh -- OECs	26512
Veh	26512
OECs	26516
Veh	26537
DMEM and BDNF -- DMEM	26541
DMEM and BDNF	26541
DMEM	26555
BDNF	26564
OECs	26569
three other groups	26588
Fig. 8 .	26609
Fig.	26609
8	26614
Combinatorial therapy	26617
functional recovery	26662
-LRB- A -RRB-	26683
Time course of percentage changes of use of left and both forelimbs	26687
Time course	26687
percentage changes of use of left and both forelimbs	26702
percentage changes	26702
use of left and both forelimbs	26724
use	26724
left and both forelimbs	26731
left	26731
both forelimbs	26740
the wall for the cylinder	26766
the wall	26766
the cylinder	26779
spinal cord injury and treatment	26814
-LRB- B -RRB-	26848
Time course	26852
changes	26867
the motor performance for reaching , grasping and retrieving a food pellet	26878
the motor performance	26878
a food pellet	26938
Time course	26957
changes	26972
mechanical thresholds	26983
left and right forepaws	27008
Time course	27037
changes	27052
thermal thresholds	27063
left and right forepaws	27085
the left forepaw	27114
two-way repeated-measures anova -LRB- P < 0.05 -RRB-	27132
two-way repeated-measures anova	27132
P < 0.05	27165
P	27165
< 0.05	27167
<	27167
0.05	27169
a time and treatment effect	27184
the cylinder test	27216
task	27260
the left forelimb for both sensory tests ; one-way repeated anova , P < 0.05 : *	27273
the left forelimb	27273
both sensory tests ; one-way repeated anova , P < 0.05 :	27295
both sensory tests	27295
one-way repeated anova , P < 0.05	27315
one-way repeated anova	27315
P < 0.05	27339
P <	27339
P	27339
0.05	27343
BDNF	27385
olfactory ensheathing cells -LRB- OECs -RRB-	27391
olfactory ensheathing cells	27391
OECs	27420
control group	27440
Veh -- DMEM	27454
Veh	27454
DMEM	27458
BDNF	27466
OECs	27471
all groups ; *** BDNF	27490
all groups	27490
all	27490
groups	27494
BDNF	27505
OECs compared with -LRB- Veh -- DMEM and Veh -- OECs -RRB-	27510
OECs	27510
Veh	27530
DMEM and Veh -- OECs	27534
DMEM and Veh	27534
OECs	27547
+ BDNF -- DMEM	27558
BDNF -- DMEM	27559
BDNF	27559
DMEM	27564
Veh -- DMEM and Veh -- OECs	27584
Veh	27584
DMEM and Veh -- OECs	27588
DMEM and Veh	27588
OECs	27601
Fig. 9 .	27609
Fig.	27609
9	27614
Poor motor performances	27617
hypersensitivity	27676
brain-derived neurotrophic factor -LRB- BDNF -RRB-	27696
brain-derived neurotrophic factor	27696
BDNF	27731
olfactory ensheathing cells -LRB- OECs -RRB-	27737
olfactory ensheathing cells	27737
OECs	27766
rats	27780
Correlation	27786
motor performances	27806
the cylinder test -LRB- A -RRB-	27829
the cylinder test	27829
A	27848
the food-pellet	27854
task -LRB- B -RRB- and thermal thresholds in individual BDNF	27879
task	27879
B	27885
thermal thresholds in individual BDNF	27892
thermal thresholds	27892
individual BDNF	27914
OECs	27930
Veh -- OECs - and BDNF --	27937
Veh	27937
OECs	27941
BDNF	27951
rats	27970
Significant correlation coefficients only for BDNF	27976
Significant correlation coefficients	27976
BDNF	28022
OEC-treated rats -LRB- included in graphs -RRB-	28027
OEC-treated rats	28027
graphs	28057
We	28067
some rubrospinal axon growth	28090
LP-OEC grafts implanted into the lesion site , but no regeneration beyond	28124
LP-OEC grafts	28124
the lesion site	28153
no regeneration	28174
Ramer	28198
et al. , 2004a	28204
et al.	28204
2004a	28212
we	28226
highly enriched LP-OECs	28250
we	28305
this	28328
cavity formation , GFAP expression at the lesion boundary	28341
cavity formation	28341
GFAP expression at the lesion boundary	28359
GFAP expression	28359
the lesion boundary	28378
the growth of NF-positive axons	28411
the growth	28411
NF-positive axons	28425
the lesion site -LRB- Richter et al. , 2005 -RRB-	28448
the lesion site	28448
Richter	28465
et al. , 2005	28473
et al.	28473
2005	28481
the present study	28491
we	28509
this improved transplantation approach	28521
a 2-week infusion of BDNF	28565
a 2-week infusion	28565
BDNF	28586
the vicinity of the cell bodies of the rubrospinal neurons	28596
the vicinity	28596
the cell bodies of the rubrospinal neurons	28612
the cell bodies	28612
the rubrospinal neurons	28631
their regenerative propensity as well as functional recovery	28675
their regenerative propensity	28675
functional recovery	28716
Fig. 1 and Table 1 for experimental design	28741
Fig. 1	28741
Table 1 for experimental design	28752
Table 1	28752
experimental design	28764
OECs	28786
the lesion	28796
cavity and glial scar formation	28819
Injury of the rat dorsolateral funiculus	28851
Injury	28851
the rat dorsolateral funiculus	28861
the formation of a lesion	28913
the formation	28913
a lesion	28930
cavitation	28944
a margin of hypertrophic , GFAP-positive astrocytes	28977
a margin	28977
hypertrophic , GFAP-positive astrocytes	28989
We	29029
this GFAPnegative area	29040
the epicenter	29066
` lesion area '	29083
the experimental groups	29107
transplanted cells	29150
cells invading from the roots and meninges	29180
cells	29180
the roots and meninges	29200
All three treatment groups	29224
Vehicle	29252
OEC , BDNF -- DMEM , BDNF -- OEC	29260
OEC	29260
BDNF -- DMEM , BDNF -- OEC	29265
BDNF	29265
DMEM , BDNF	29270
OEC	29281
smaller lesion areas	29303
our control group -LRB- Vehicle -- DMEM ; Fig. 2A -RRB-	29329
our control group	29329
Vehicle	29348
DMEM ; Fig. 2A	29356
DMEM	29356
Fig. 2A	29362
these measurements	29376
significance	29411
P = 0.14 BDNF	29425
P =	29425
0.14 BDNF	29429
OEC group ; Fig 3A	29439
OEC group	29439
Fig 3A	29450
Transplantation of OECs alone -LRB- Vehicle -- OEC -RRB-	29459
Transplantation	29459
OECs alone -LRB- Vehicle -- OEC -RRB-	29478
OECs alone	29478
OECs	29478
Vehicle -- OEC	29490
Vehicle	29490
OEC	29498
combination with BDNF treatment of the rubrospinal cell	29509
combination	29509
BDNF treatment of the rubrospinal cell	29526
BDNF treatment	29526
the rubrospinal cell	29544
BDNF -- OEC	29573
BDNF	29573
OEC	29578
the size	29594
the cavity area -LRB- Figs 2 and 3B -RRB-	29606
the cavity area	29606
Figs 2 and 3B	29623
Figs 2	29623
3B	29634
a decreased percentage of lesion area occupied by cavitation -LRB- Fig. 3C -RRB-	29667
a decreased percentage	29667
lesion area occupied by cavitation -LRB- Fig. 3C -RRB-	29693
lesion area	29693
cavitation -LRB- Fig. 3C -RRB-	29717
cavitation	29717
Fig. 3C	29729
Both groups	29739
OECs -LRB- Vehicle -- OEC and BDNF -- OEC ; Fig. 2B and C -RRB-	29761
OECs	29761
Vehicle	29767
OEC and BDNF -- OEC ; Fig. 2B and C	29775
OEC and BDNF	29775
OEC ; Fig. 2B and C	29788
OEC	29788
Fig. 2B and C	29793
reduced immunoreactivity	29815
GFAP	29844
less hypertrophy of reactive astrocytes -LRB- Fig. 3D -RRB-	29864
less hypertrophy	29864
reactive astrocytes -LRB- Fig. 3D -RRB-	29884
reactive astrocytes	29884
Fig. 3D	29905
the control group	29928
Cell body treatment with BDNF combined with DMEM at the spinal cord	29947
Cell body treatment	29947
BDNF combined with DMEM at the spinal cord	29972
BDNF	29972
DMEM	29991
the spinal cord	29999
a trend	30027
smaller cavity areas and GFAP immunoreactivity	30043
smaller cavity areas	30043
GFAP immunoreactivity	30068
these parameters	30100
significance	30133
the control group	30165
Fig. 3B -- D	30184
Fig. 3B	30184
D	30192
OEC survival	30206
cell body treatment	30239
BDNF -LRB- Fig. 4 , two-way repeated anova ,	30264
BDNF	30264
Fig. 4 , two-way repeated anova	30270
Fig. 4	30270
two-way repeated anova	30278
P	30302
0.95 for the treatment · distance interaction	30306
0.95	30306
the treatment · distance interaction	30315
summary , the minimal neuroprotection	30357
summary	30357
the minimal neuroprotection	30366
lesion area measurement	30407
the combination of OECs with BDNF	30444
the combination	30444
OECs with BDNF	30463
OECs	30463
BDNF	30473
OEC or BDNF treatment	30501
alone , i.e. the effects were not additive	30523
alone	30523
i.e. the effects were not additive	30530
i.e.	30530
the effects	30535
the combination of OECs and BDNF	30577
the combination	30577
OECs and BDNF	30596
an additive effect	30623
astrocytic hypertrophy	30645
cavity formation and percentage of the lesion area occupied by cavitation	30669
cavity formation and percentage	30669
the lesion area	30704
cavitation	30732
transplantation of OECs	30750
transplantation	30750
OECs	30769
the observed beneficial effects on GFAP immunoreactivity and cavity formation	30804
the observed beneficial effects	30804
GFAP immunoreactivity and cavity formation	30839
GFAP immunoreactivity	30839
cavity formation	30865
Prevention	30883
rubrospinal axon retraction	30897
We	30925
the regeneration of rubrospinal axons	30942
the regeneration	30942
rubrospinal axons	30962
them	30992
the anterogradely	31002
tracer BDA	31032
rubrospinal axons	31054
axotomy -LRB- Ye & Houle , 1997 ; Jin et al. , 2002 -RRB-	31086
axotomy	31086
Ye	31095
& Houle , 1997 ; Jin et al. , 2002	31098
Houle , 1997 ; Jin et al.	31100
Houle , 1997	31100
Houle	31100
1997	31107
Jin et al.	31113
Jin	31113
et al.	31117
2002	31125
our control condition -LRB- Veh -- DMEM ; Fig. 2A -RRB-	31139
our control condition	31139
Veh	31162
DMEM ; Fig. 2A	31166
DMEM	31166
Fig. 2A	31172
rostral ⁄ caudal DMEM injections	31191
caudal DMEM injections	31201
most rubrospinal axons	31225
1700 µm -LRB- ± 323 µm -RRB-	31260
1700 µm	31260
± 323 µm	31269
±	31269
323 µm	31271
rostral to the lesion center	31279
rostral	31279
the lesion center	31290
contrast	31312
all three experimental conditions	31325
BDNF -- DMEM , Veh -- OECs and their combination BDNF -- OEC	31360
BDNF	31360
DMEM , Veh -- OECs and their combination BDNF -- OEC	31365
DMEM	31365
Veh -- OECs and their combination BDNF -- OEC	31371
Veh	31371
OECs and their combination BDNF	31376
OECs	31376
their combination BDNF	31385
OEC	31408
the bulk of these rubrospinal axons	31414
the bulk	31414
these rubrospinal axons	31426
500 µm	31468
the epicenter -LRB- P < 0.01 ; Figs 2A and 5A -RRB-	31488
the epicenter	31488
P < 0.01 ; Figs 2A and 5A	31503
P	31503
< 0.01 ; Figs 2A and 5A	31505
< 0.01	31505
<	31505
0.01	31507
Figs 2A and 5A	31513
Figs 2A	31513
5A	31525
we	31536
atrophic retracting axons	31566
axons	31613
it	31620
most anterogradely traced axons	31649
most	31649
axons	31675
the host tissue	31694
the proximity of transplanted cells	31739
the proximity	31739
transplanted cells	31756
The straight course of many of these axons	31776
The straight course	31776
many of these axons	31799
many	31799
these axons	31807
the interpretation	31826
these	31850
these differences in rubrospinal axon profiles at the rostral lesion edge	31890
these differences	31890
rubrospinal axon profiles at the rostral lesion edge	31911
rubrospinal axon profiles	31911
the rostral lesion edge	31940
differences in the efficacy of anterograde tracing	31980
differences	31980
the efficacy of anterograde tracing	31995
the efficacy	31995
anterograde tracing	32011
anterograde	32011
The number	32032
rubrospinal axons	32046
BDA	32076
coronal -LRB- i.e. cross	32091
coronal	32091
i.e.	32100
sections taken at C2	32113
sections	32113
C2	32131
the control group	32147
this	32170
significance -LRB- P = 0.11 ; Fig. 5B -RRB-	32189
significance	32189
P	32203
= 0.11 ; Fig. 5B	32205
= 0.11	32205
Fig. 5B	32213
the three treatment groups and the Vehicle	32230
the three treatment groups	32230
the Vehicle	32261
DMEM-treated control group	32273
all three treatments	32308
i.e. BDNF -- DMEM , Veh -- OEC or their combination	32330
i.e. BDNF	32330
DMEM , Veh -- OEC or their combination	32340
DMEM	32340
Veh	32346
OEC	32350
their combination	32357
the retraction of rubrospinal axons	32396
the retraction	32396
rubrospinal axons	32414
the lesion epicenter -LRB- P < 0.01 ; Fig. 5A -RRB-	32437
the lesion epicenter	32437
P < 0.01 ; Fig. 5A	32459
P	32459
< 0.01 ; Fig. 5A	32461
< 0.01	32461
<	32461
0.01	32463
Fig. 5A	32469
Fig.	32469
5A	32474
neither treatment condition	32483
regeneration of rubrospinal axons	32520
regeneration	32520
rubrospinal axons	32536
the transplanted LP-OECs	32573
these limited effects on rubrospinal regeneration	32607
these limited effects	32607
rubrospinal regeneration	32632
OECs	32658
various axonal populations -LRB- NF-200 and ⁄ or tub-positive structures -RRB-	32685
various axonal populations	32685
NF-200 and ⁄ or tub-positive structures	32713
NF-200 and ⁄	32713
tub-positive structures	32729
the OEC-filled lesion site	32759
the cell body treatment -LRB- Fig. 6 ; one-way anova , P = 0.43 -RRB-	32802
the cell body treatment	32802
Fig. 6 ; one-way anova , P = 0.43	32827
Fig. 6	32827
one-way anova , P = 0.43	32835
one-way anova	32835
P = 0.43	32850
P	32850
0.43	32854
We	32861
the sprouting of identified supra-spinal axons and peripheral afferents	32883
the sprouting	32883
identified supra-spinal axons and peripheral afferents	32900
identified supra-spinal axons	32900
peripheral afferents	32934
The immunoreactivity	32956
supra-spinal fibers	32981
SERT-positive fibers ; Fig. 7A -- C	33024
SERT-positive fibers	33024
Fig. 7A -- C	33046
Fig. 7A	33046
C	33054
TH-positive fibers ; Fig. 7D -- F	33076
TH-positive fibers	33076
Fig. 7D -- F	33096
Fig. 7D	33096
F	33104
the rostral lesion transplant interface	33128
caudal to the transplant in all groups	33173
the transplant in all	33183
the transplant	33183
all	33201
only a few axons	33222
the engrafted OECs	33249
the	33249
OECs	33263
Axonal density measurements	33269
more SERT	33320
more	33320
TH-positive fibers rostral to the lesion in OEC	33335
TH-positive fibers rostral	33335
the lesion in OEC	33365
the lesion	33365
OEC	33379
spinal cords -LRB- Veh -- OEC and BDNF -- OEC -RRB- compared with controls	33391
spinal cords	33391
Veh	33405
OEC and BDNF -- OEC	33409
OEC and BDNF	33409
OEC	33422
controls	33441
The density of peripheral afferents positive for substance-P -LRB- Sub-P -RRB-	33451
The density	33451
peripheral afferents positive for substance-P -LRB- Sub-P -RRB-	33466
peripheral afferents positive for substance-P	33466
peripheral afferents	33466
substance-P	33500
Sub-P	33513
higher caudal	33524
the lesion site	33541
this phenomenon	33562
the groups -LRB- Fig. 7G -- I -RRB-	33616
the groups	33616
Fig. 7G -- I	33628
Fig. 7G	33628
I	33636
contrast	33643
small-diameter peptidergic nociceptive fibers containing CGRP	33653
small-diameter peptidergic nociceptive fibers	33653
CGRP	33710
the OEC transplanted rats , both at the cranial and caudal lesion margins	33743
the OEC transplanted rats	33743
both at the cranial and caudal lesion margins	33770
both	33770
the cranial and caudal lesion margins	33778
the epicenters of the transplants -LRB- Fig. 7J -- L -RRB-	33834
the epicenters	33834
the transplants -LRB- Fig. 7J -- L -RRB-	33852
the transplants	33852
Fig. 7J -- L	33869
Fig. 7J	33869
L	33877
the density of CGRP-positive fibers	33887
the density	33887
CGRP-positive fibers	33902
highest inside the transplant with Vehicle -- OEC treatment	33927
highest inside the transplant with Vehicle	33927
highest	33927
the transplant with Vehicle	33942
the transplant	33942
Vehicle	33962
OEC treatment	33970
the combination of OECs with BDNF	33985
the combination	33985
OECs with BDNF	34004
OECs	34004
BDNF	34014
significantly more CGRP-positive axons	34031
1.5 mm rostral to the lesion	34085
1.5 mm rostral	34085
the lesion	34103
the OECs grafts -LRB- Fig. 7K and L -RRB-	34119
the OECs grafts	34119
Fig. 7K and L	34136
Fig. 7K	34136
L	34148
OEC grafts	34158
pronounced effects on the sprouting of SERT - , TH - and CGRPpositive axons	34173
pronounced effects on the sprouting of SERT -	34173
pronounced effects	34173
the sprouting of SERT -	34195
the sprouting	34195
SERT	34212
TH	34219
CGRPpositive axons	34227
the growth of the latter population	34251
the growth	34251
the latter population	34265
the application of BDNF	34303
the application	34303
BDNF	34322
the vicinity of the red nucleus in the midbrain	34330
the vicinity	34330
the red nucleus in the midbrain	34346
the red nucleus	34346
the midbrain	34365
Functional outcomes	34379
the behavioral outcomes of our treatments	34409
the behavioral outcomes	34409
our treatments	34436
forelimb function	34454
the left -LRB- injured -RRB- side of the spinal cord	34475
the left -LRB- injured -RRB- side	34475
injured	34485
the spinal cord	34502
we	34519
the usage	34532
the left forelimb for the cylinder test and the food-pellet reaching task	34545
the left forelimb for the cylinder test	34545
the left forelimb	34545
the cylinder test	34567
the food-pellet reaching task	34589
the food-pellet	34589
task	34614
Figure 8A	34620
the time course of forelimb usage	34642
the time course	34642
forelimb usage	34661
vertical exploration of a Plexiglas cylinder	34683
vertical exploration	34683
a Plexiglas cylinder	34707
the usage of the left forelimb	34744
the usage	34744
the left forelimb	34757
left plus both	34789
left	34789
both	34799
rats	34826
25 %	34845
the left or right forelimb	34854
50 % with both simultaneously	34889
50 %	34889
control values	34926
75 -- 80 % for all groups	34958
75	34958
80 % for all groups	34961
80 %	34961
all groups	34969
spinal cord injury	34987
the literature -LRB- Liu et al. , 1999 ; Schallert et al. , 2000 -RRB-	35023
the literature	35023
Liu	35039
et al. , 1999 ; Schallert et al. , 2000	35043
et al.	35043
1999 ; Schallert et al.	35051
1999	35051
Schallert et al.	35057
Schallert	35057
et al.	35067
2000	35075
spinal cord injury	35088
the forelimb usage	35108
30	35152
40 % in rats , who received control treatment or any of the two monotreatments	35155
40 %	35155
rats , who received control treatment or any of the two monotreatments	35162
rats	35162
control treatment or any of the two monotreatments	35181
control treatment	35181
any of the two monotreatments	35202
any	35202
the two monotreatments	35209
it	35247
5 %	35273
rats treated with the combinatorial treatment of BDNF and OECs	35279
rats	35279
the combinatorial treatment of BDNF and OECs	35297
the combinatorial treatment	35297
BDNF and OECs	35328
the left forelimb	35359
95 % of the rears	35404
95 %	35404
the rears	35411
the right paw	35441
This diminution in the use of the left forelimb in BDNF -- OEC-treated rats	35456
This diminution	35456
the use of the left forelimb in BDNF -- OEC-treated rats	35475
the use	35475
the left forelimb in BDNF -- OEC-treated rats	35486
the left forelimb in BDNF	35486
the left forelimb	35486
BDNF	35507
OEC-treated rats	35512
the first 2 weeks	35546
injury -LRB- equivalent to the flow period of the osmotic minipump -RRB-	35570
injury	35570
the flow period of the osmotic minipump	35592
the flow period	35592
the osmotic minipump	35611
the usage	35650
the levels of other groups	35682
the levels	35682
other groups	35696
The rats	35710
a more sophisticated motor task	35740
proximal as well as distal muscles : the food-pellet reaching task	35782
proximal as well as distal muscles	35782
the food-pellet reaching task	35818
the food-pellet	35818
task	35843
Chan	35849
et al. , 2005	35854
et al.	35854
2005	35862
Figure 8B	35869
the time course	35891
motor skill changes for the food-pellet reaching task scaled on 10 points	35910
motor skill changes	35910
the food-pellet reaching task scaled on 10 points	35934
the food-pellet	35934
task scaled on 10 points	35959
task	35959
10 points	35974
injury	35992
all rats	36000
touch , grasp	36037
touch	36037
grasp	36044
the food pellet	36063
average score of 8 , see Chan et al. , 2005 for details of the scale	36080
average score	36080
8 , see Chan et al. , 2005 for details of the scale	36097
8	36097
Chan	36104
et al. , 2005 for details of the scale	36109
et al.	36109
2005 for details of the scale	36117
2005	36117
details of the scale	36126
details	36126
the scale	36137
spinal cord injury	36155
control rats as well as OEC-treated rats	36175
control rats	36175
control	36175
rats	36183
OEC-treated rats	36199
the pellet	36253
it -LRB- score 3 -RRB- during the first 3 weeks	36285
it -LRB- score 3 -RRB-	36285
it	36285
score 3	36289
the first 3 weeks	36305
4 weeks	36339
they	36347
score 5	36385
score 7	36423
the food pellet	36432
contrast	36452
BDNF -- OEC-treated rats	36462
BDNF	36462
OEC-treated rats	36467
injury compared with the control group	36523
injury	36523
the control group	36544
their left injured forelimb	36592
average score of 2	36646
average score	36646
2	36663
the 4 weeks of observation	36673
the 4 weeks	36673
observation	36688
BDNF-treated rats	36707
the second and third week in comparison	36770
the second and third week	36770
comparison	36799
OECtreated and control rats	36813
they	36842
the OEC-treated -LRB- P > 0.95 -RRB- and control -LRB- P = 0.3 -RRB-	36905
the OEC-treated	36905
P > 0.95	36922
P	36922
> 0.95	36924
>	36924
0.95	36926
control	36936
P	36945
0.3	36949
rats by 4 weeks	36954
rats	36954
4 weeks	36962
These observations	36971
the functional impairments observed in the cylinder and reaching tests	37004
the functional impairments	37004
the cylinder	37043
tests	37069
the combination of OEC transplants and BDNF	37094
the combination	37094
OEC transplants and BDNF	37113
OEC transplants	37113
BDNF	37133
this delay and diminution	37150
the functional motor recovery of the left injured forelimb	37179
the functional motor recovery	37179
the left injured forelimb	37212
we	37239
this	37257
a sensory alteration in the forepaws	37278
a sensory alteration	37278
the forepaws	37302
Figure 8C and D	37316
time courses of sensory thresholds to mechanical and thermal stimulation	37344
time courses	37344
sensory thresholds to mechanical and thermal stimulation	37360
sensory thresholds	37360
mechanical and thermal stimulation	37382
spinal cord injury and treatment	37434
BDNF-treated or OEC-treated rats	37477
a decreased mechanical and thermal threshold	37520
rats	37590
P = 0.26 and P = 0.2 for weeks 2 and 3 , respectively , in Fig. 8D	37596
P = 0.26	37596
P	37596
= 0.26	37598
P = 0.2 for weeks 2 and 3 , respectively , in Fig. 8D	37609
P	37609
0.2	37613
weeks 2 and 3 , respectively , in Fig. 8D	37621
weeks 2 and 3 , respectively ,	37621
weeks 2 and 3	37621
Fig. 8D	37653
BDNF	37668
OEC-treated rats	37674
a significant diminution	37698
sensory thermal thresholds	37726
the duration of the cell body treatment in comparison	37757
the duration	37757
the cell body treatment in comparison	37773
the cell body treatment	37773
comparison	37800
the control rats	37816
this	37838
the other groups	37872
4 weeks after spinal cord injury and treatment -LRB- P = 0.07 -RRB-	37892
4 weeks	37892
spinal cord injury and treatment -LRB- P = 0.07 -RRB-	37906
spinal cord injury and treatment	37906
P	37940
0.07	37944
the motor scores	37960
the sensory thresholds	37985
a strong correlation -LRB- R = 0.58 , P < 0.01 -RRB-	38017
a strong correlation	38017
R = 0.58 , P < 0.01	38039
R	38039
= 0.58 , P < 0.01	38041
= 0.58 , P <	38041
0.58 , P	38043
0.58	38043
P	38049
0.01	38053
poor motor performances and low thermal thresholds in individual BDNF --	38067
poor motor performances	38067
low thermal thresholds in individual BDNF	38095
low thermal thresholds	38095
individual BDNF	38121
OEC rats -LRB- Fig. 9 -RRB-	38137
OEC rats	38137
Fig. 9	38147
the delay and diminution in functional recovery	38162
the delay and diminution	38162
functional recovery	38190
BDNF	38222
OEC rats	38227
an alteration in mechanical and thermal sensations	38263
an alteration	38263
mechanical and thermal sensations	38280
Discussion Combinatorial treatments	38316
the multifaceted problems	38388
spinal cord injury	38434
Lu	38454
et al. , 2003	38457
et al.	38457
2003	38465
Nikulina et al. , 2004	38471
Nikulina	38471
et al. , 2004	38480
et al.	38480
2004	38488
Pearse et al. , 2004	38494
Pearse	38494
et al. , 2004	38501
et al.	38501
2004	38509
Fouad et al. , 2005	38515
Fouad	38515
et al. , 2005	38521
et al.	38521
2005	38529
Steinmetz et al. , 2005	38535
Steinmetz	38535
et al. , 2005	38545
et al.	38545
2005	38553
we	38565
the first time	38579
the potential for detrimental effects of a combinatorial therapy	38594
the potential	38594
detrimental effects of a combinatorial therapy	38612
detrimental effects	38612
a combinatorial therapy	38635
We	38660
transplantation of highly enriched LP-derived OECs -LRB- LPOECs -RRB-	38672
transplantation	38672
highly enriched LP-derived OECs -LRB- LPOECs -RRB-	38691
highly enriched LP-derived OECs	38691
LPOECs	38724
cervical spinal cord injury sites of rats with the infusion of BDNF	38737
cervical spinal cord injury sites	38737
rats with the infusion of BDNF	38774
rats	38774
the infusion of BDNF	38784
the infusion	38784
BDNF	38800
the red nucleus	38808
All treatment groups	38825
BDNF	38852
OECs	38864
BDNF -- OECs	38879
BDNF	38879
OECs	38884
the lesion size of the spinal cord	38906
the lesion size	38906
the spinal cord	38925
the both groups with OECs	38946
the both groups	38946
OECs	38967
cavitation and astrocytic hypertrophy	38980
cavitation	38980
astrocytic hypertrophy	38995
Each treatment alone as well as in combination	39019
Each treatment	39019
combination	39054
the number of rubrospinal axons rostral	39076
the number	39076
rubrospinal axons rostral	39090
the lesion site	39119
no group	39145
rubrospinal axon regeneration	39161
the OECs	39199
the distal spinal cord	39213
surprisingly the combinatorial treatment	39246
addition	39291
no further benefits	39311
single treatment	39338
impaired functional recovery	39356
the forelimb	39388
the injury side -LRB- left -RRB-	39404
the injury side	39404
left	39421
hypersensitivity of the forepaw	39450
hypersensitivity	39450
the forepaw	39470
The neuroprotective effects of transplanting neonatal LP-OECs	39483
The neuroprotective effects	39483
neonatal LP-OECs	39528
previous observations	39590
adult rat OB-derived OECs	39618
the injured dorsolateral funiculus in Fischer rats	39647
the injured dorsolateral funiculus	39647
Fischer rats	39685
Ruitenberg et al. , 2003	39699
Ruitenberg	39699
et al.	39710
2003	39718
transduction of OB-OECs with BDNF and ⁄ or NT-3-expressing viral vectors	39740
transduction	39740
OB-OECs with BDNF and ⁄ or NT-3-expressing viral vectors	39756
OB-OECs	39756
BDNF and ⁄ or NT-3-expressing viral vectors	39769
BDNF and ⁄	39769
NT-3-expressing viral vectors	39783
they	39814
lesion volumes	39827
the spinal cord cytoarchitecture	39856
the injured dorsolateral funiculus	39892
Ruitenberg et al. , 2003	39928
Ruitenberg	39928
et al.	39939
2003	39947
Our combination of LP-OECs with BDNF infusion to the midbrain	39954
Our combination	39954
LP-OECs with BDNF infusion to the midbrain	39973
LP-OECs	39973
BDNF infusion to the midbrain	39986
BDNF infusion	39986
the midbrain	40003
significant neuroprotective effects	40032
the trend with each single treatment	40076
the trend	40076
each single treatment	40091
no apparent additive effects	40125
All three treatment groups	40155
more rubrospinal axons	40189
close vicinity	40215
the epicenter	40233
less axonal retraction ⁄ dieback and ⁄	40268
the control group	40333
It	40352
these two scenarios in our experiments	40386
these two scenarios	40386
our experiments	40409
The straight course	40426
many rubrospinal axons in their original localization within the tract	40449
many rubrospinal axons	40449
their original localization within the tract	40475
their original localization	40475
the tract	40510
the interpretation of axonal protection -LRB- i.e. less retraction -RRB-	40527
the interpretation	40527
axonal protection -LRB- i.e. less retraction -RRB-	40549
axonal protection	40549
i.e. less retraction	40568
i.e.	40568
less retraction	40573
retraction and regrowth	40602
the effects of BDNF plus OECs	40634
the effects	40634
BDNF plus OECs	40649
BDNF	40649
OECs	40659
the prevention of retraction	40687
the prevention	40687
retraction	40705
BDNF or OEC application	40738
Rubrospinal axons	40769
the transplanted cells	40819
the site	40845
OEC injection	40857
the injury	40883
the cells that filled the lesion site	40917
the cells	40917
the lesion site	40939
we	40962
transplanted cells	40988
the axonal stumps of the rubrospinal tract	41035
the axonal stumps	41035
the rubrospinal tract	41056
⁄ or some rubrospinal axons	41083
⁄	41083
some rubrospinal axons	41088
the transplanted cells	41139
there	41163
no evidence for rubrospinal regeneration	41173
no evidence	41173
rubrospinal regeneration	41189
the injury site	41229
These findings	41246
line	41268
the observations	41278
Ruitenberg and co-workers	41298
no sprouting of rubrospinal axons	41335
no sprouting	41335
rubrospinal axons	41351
adult OB-OEC-filled lesion sites	41374
these	41415
trophic factors -LRB- Ruitenberg et al. , 2003 -RRB-	41448
trophic factors	41448
Ruitenberg	41465
et al. , 2003	41476
et al.	41476
2003	41484
our previous studies with LP-OECs -LRB- Ramer et al. , 2004a -RRB-	41494
our previous studies	41494
LP-OECs -LRB- Ramer et al. , 2004a -RRB-	41520
LP-OECs	41520
Ramer	41529
et al. , 2004a	41535
et al.	41535
2004a	41543
we	41550
some rubrospinal axons	41562
LP-OECs	41591
the lesion site	41602
the different injection modes : proximal and distal	41648
the different injection modes	41648
the injury in the present study	41702
the injury	41702
the present study	41716
the injury site in the previous study -LRB- Ramer et al. , 2004a -RRB-	41753
the injury site	41753
the previous study -LRB- Ramer et al. , 2004a -RRB-	41772
the previous study	41772
Ramer	41792
et al. , 2004a	41798
et al.	41798
2004a	41806
the different growth factors made by early passage OECs	41830
the different growth factors	41830
early passage OECs	41867
later passage OECs	41900
Pastrana et al. , 2006 ; Au et al. , 2007 ; Franssen et al. , 2007	41920
Pastrana	41920
et al. , 2006 ; Au et al. , 2007 ; Franssen et al. , 2007	41929
et al. , 2006	41929
et al.	41929
2006	41937
Au et al. , 2007	41943
Au	41943
et al. , 2007	41946
et al.	41946
2007	41954
Franssen et al. , 2007	41960
Franssen	41960
et al. , 2007	41969
et al.	41969
2007	41977
Our BDNF treatments	41984
rubrospinal axon growth	42029
the transplants	42058
There	42075
most likely differences	42085
the neurotrophic ⁄	42117
tropic effects of BDNF	42136
tropic effects	42136
BDNF	42154
transplanted cells -LRB- Ruitenberg et al. , 2003 -RRB-	42176
transplanted cells	42176
Ruitenberg	42196
et al. , 2003	42207
et al.	42207
2003	42215
BDNF that is applied to the cell bodies	42225
BDNF	42225
the cell bodies	42249
the growing rubrospinal axons	42290
BDNF infusion to the red nucleus	42321
BDNF infusion	42321
the red nucleus	42338
BDNF mRNA	42364
these neurons -LRB- Kobayashi et al. , 1997 -RRB-	42377
these neurons	42377
Kobayashi	42392
et al. , 1997	42402
et al.	42402
1997	42410
the first scenario	42420
the transplanted cells	42440
a gradient	42474
BDNF	42489
a neurotropic attractant in the lesion center	42505
a neurotropic attractant	42505
the lesion center	42533
the latter scenario	42561
the source	42581
the axons of the proximal tract themselves	42601
the axons	42601
the proximal tract themselves	42614
the proximal tract	42614
the gradient	42645
such attraction into the lesion	42671
such attraction	42671
the lesion	42692
our previous studies	42730
we	42751
stimulation of rubrospinal axon growth	42763
stimulation	42763
rubrospinal axon growth	42778
peripheral nerve transplants	42807
BDNF cell body treatment	42841
Kobayashi	42867
et al. , 1997 ; Kwon et al. , 2002	42877
et al.	42877
1997 ; Kwon et al.	42885
1997	42885
Kwon et al.	42891
Kwon	42891
et al.	42896
2002	42904
contrast	42920
no stimulation of rubrospinal sprouting into the OEC-filled lesion sites	42929
no stimulation	42929
rubrospinal sprouting into the OEC-filled lesion sites	42947
the OEC-filled lesion	42974
this treatment in the present study	43020
this treatment	43020
the present study	43038
The survival time in these former studies	43057
The survival time	43057
these former studies	43078
> 10 weeks	43111
>	43111
10 weeks	43113
the present study , which could have played some role	43131
the present study	43131
some role	43174
longer survival times	43191
more regeneration	43236
we	43255
time for regeneration	43268
time	43268
regeneration	43277
the main reason for these differences	43297
the main reason	43297
these differences	43317
our hands	43342
some rubrospinal axons	43352
peripheral nerve transplants	43391
a month -LRB- unpublished data , W.T. -RRB-	43427
a month	43427
unpublished data	43436
W.T.	43454
These findings	43461
important differences	43486
these two types of bridges , including the fact that our OECs were	43516
these two types	43516
bridges	43535
the fact that our OECs were	43554
the fact	43554
our OECs	43568
an enriched population	43587
OECs	43613
a mixture of cells with extensive extracellular matrix encountered in a nerve	43630
a mixture	43630
cells with extensive extracellular matrix encountered in a nerve	43643
cells	43643
extensive extracellular matrix encountered in a nerve	43654
extensive extracellular matrix	43654
a nerve	43700
-LRB- 2 -RRB- randomly oriented rather than aligned by long basal lamina tubes	43709
randomly	43713
long basal lamina tubes	43754
a	43783
mouse-to-rat xenograft	43785
that may stimulate an adverse immune response rather than a nerve autograft	43808
that may stimulate an adverse immune response	43808
an adverse immune response	43827
a nerve autograft	43866
-LRB- 4 -RRB- a possibly weaker source of trophic ⁄ tropic factors	43889
a possibly weaker source	43893
trophic ⁄ tropic factors	43921
peripheral nerve grafts	43951
A recent report by Xiao et al. -LRB- 2007 -RRB-	43976
A recent report by Xiao et al.	43976
A recent report by Xiao	43976
A recent report	43976
Xiao	43995
et al.	44000
2007	44008
extensive rubrospinal regeneration	44022
transplantation	44063
a cell line	44082
human adult olfactory neuroepithelial progenitors cells	44107
human adult olfactory neuroepithelial progenitors	44107
cells	44157
up to 40 passages	44176
these cells	44201
epigenetic events	44231
an immortalized line -LRB- now commercialized by RhinoCytes -RRB-	44263
an	44263
line -LRB- now commercialized by RhinoCytes -RRB-	44279
line	44279
RhinoCytes	44307
primary cultures of OECs	44320
primary cultures	44320
OECs	44340
sphere-forming behavior and bear little similarity	44357
these	44413
cells.We	44432
an independent replication	44455
the extensive rubrospinal regeneration claimed by these authors	44485
the extensive rubrospinal regeneration	44485
these authors	44535
We	44550
functional recovery ⁄ compensation in a cylinder	44568
functional recovery ⁄ compensation	44568
a cylinder	44606
task	44630
newborn mouse LP-OEC transplants in contrast	44638
newborn mouse LP-OEC transplants	44638
contrast	44674
previous studies	44686
behavioral improvement	44717
a ropewalking task after adult rat OB-OECs transplants	44743
a ropewalking task	44743
adult rat OB-OECs transplants	44768
Li	44799
et al. , 1997 , 1998 ; Ruitenberg et al. , 2003 ; Sasaki et al. , 2004	44802
et al.	44802
1997 , 1998 ; Ruitenberg et al. , 2003 ; Sasaki et al.	44810
1997 , 1998	44810
1997	44810
1998	44816
Ruitenberg et al. , 2003	44822
Ruitenberg	44822
et al. , 2003	44833
et al.	44833
2003	44841
Sasaki et al.	44847
Sasaki	44847
et al.	44854
2004	44862
This difference	44869
intrinsic differences between cell types	44901
intrinsic differences	44901
cell types	44931
LP vs. OB	44943
LP	44943
OB	44950
Au & Roskams , 2003	44954
Au & Roskams	44954
2003	44968
Richter et al. , 2005 -RRB-	44974
Richter	44974
et al.	44982
2005	44990
the age -LRB- neonatal vs. adult donors ; Lipson et al. ,	44999
the age	44999
neonatal vs. adult donors ; Lipson et al.	45008
neonatal vs. adult donors	45008
neonatal	45008
adult donors	45021
Lipson et al.	45035
Lipson	45035
et al.	45042
2003	45050
xenotransplant side effects and the behavioral test	45060
xenotransplant side effects	45060
the behavioral test	45092
the combination	45135
OECs transplants with BDNF treatment of rubrospinal neurons impaired	45154
OECs transplants	45154
BDNF treatment of rubrospinal neurons impaired	45176
BDNF treatment	45176
rubrospinal neurons impaired	45194
rubrospinal neurons	45194
functional recovery	45235
This apparent motor impairment	45256
sensory hypersensitivity	45303
the duration of the cell body treatment	45332
the duration	45332
the cell body treatment	45348
the density of CGRP-positive axons in the spinal cord	45386
the density	45386
CGRP-positive axons in the spinal cord	45401
CGRP-positive axons	45401
the spinal cord	45424
the lesion in the combined BDNF -- OEC treatment group	45452
the lesion in the combined BDNF	45452
the lesion	45452
the combined BDNF	45466
OEC treatment group	45484
mechanical and thermal hypersensitivity	45514
mechanical	45514
thermal hypersensitivity	45529
adult rat OB-OECs transplantations	45578
a photochemical lesion	45623
the spinal cord -LRB- Verdu et al. , 2003 ; Lopez - Vales et al. , 2004 -RRB-	45649
the spinal cord	45649
Verdu	45666
et al. , 2003 ; Lopez - Vales et al. , 2004	45672
et al.	45672
2003 ; Lopez - Vales et al.	45680
2003 ; Lopez	45680
2003	45680
Lopez	45686
Vales et al.	45693
Vales	45693
et al.	45699
2004	45707
we	45714
altered sensitivity thresholds	45730
our LP-OEC -LRB- vehicle -- OECs -RRB-	45764
our LP-OEC	45764
vehicle -- OECs	45776
vehicle	45776
OECs	45784
transplanted group	45796
Neither	45816
we	45828
lowered thresholds	45839
BDNF infusion alone -LRB- BDNF -- DMEM -RRB-	45864
BDNF infusion alone	45864
BDNF infusion	45864
BDNF -- DMEM	45885
BDNF	45885
DMEM	45891
the lowered sensory thresholds	45905
our combined OEC	45948
BDNF group	45965
an unexpected combinatorial effect	45988
We	46024
the possible mechanism	46049
It	46073
the combined group	46093
higher levels of trophic factors	46117
higher levels	46117
trophic factors	46134
the site of spinal cord injury than the single treatment groups	46153
the site	46153
spinal cord injury than the single treatment groups	46165
spinal cord injury	46165
the single treatment groups	46189
example	46222
adult hamster and rat OB-OECs	46231
different types	46282
neurotrophic factors	46301
BDNF and nerve growth factor -LRB- NGF -RRB-	46331
BDNF and nerve growth factor	46331
NGF	46361
Boruch	46367
et al. , 2001	46374
et al.	46374
2001	46382
Lipson et al. , 2003	46388
Lipson	46388
et al. , 2003	46395
et al.	46395
2003	46403
Sasaki et al. , 2006b	46409
Sasaki	46409
et al. , 2006b	46416
et al.	46416
2006b	46424
Wang et al. , 2006	46430
Wang	46430
et al. , 2006	46435
et al.	46435
2006	46443
Pastrana et al. , 2007	46449
Pastrana	46449
et al. , 2007	46458
et al.	46458
2007	46466
this	46477
the case for LP-OECs	46489
the case	46489
LP-OECs	46502
addition	46514
the exogenous delivery of BDNF at the red nucleus level	46524
the exogenous delivery	46524
BDNF at the red nucleus level	46550
BDNF	46550
the red nucleus level	46558
the mRNA expression of BDNF	46590
the mRNA expression	46590
BDNF	46613
rubrospinal neurons -LRB- Kobayashi et al. , 1997 -RRB-	46621
rubrospinal neurons	46621
Kobayashi	46642
et al. , 1997	46652
et al.	46652
1997	46660
spinal BDNF delivery via axonal transport	46687
spinal BDNF delivery	46687
axonal transport	46712
their terminals	46732
the literature	46758
conflicting	46776
BDNF	46789
sensitization	46817
dorsal horn neurons	46834
Kerr	46855
et al. , 1999	46860
et al.	46860
1999	46868
Mannion et al. , 1999	46874
Mannion	46874
et al. , 1999	46882
et al.	46882
1999	46890
Heppenstall & Lewin , 2001	46896
Heppenstall & Lewin	46896
2001	46917
Pezet et al. , 2002	46923
Pezet	46923
et al. , 2002	46929
et al.	46929
2002	46937
Coull et al. , 2005	46943
Coull	46943
et al. , 2005	46949
et al.	46949
2005	46957
the role of NGF in pain mechanisms	46968
the role	46968
NGF in pain mechanisms	46980
NGF	46980
pain mechanisms	46987
Christensen & Hulsebosch , 1997 ; Pezet et al.	47024
Christensen & Hulsebosch , 1997	47024
Christensen & Hulsebosch	47024
1997	47050
Pezet et al.	47056
Pezet	47056
et al.	47062
2001 ; Priestley et al.	47070
2001	47070
Priestley et al.	47076
Priestley	47076
et al.	47086
2002 ; Pezet & McMahon , 2006	47094
2002	47094
Pezet & McMahon , 2006	47100
Pezet & McMahon	47100
2006	47117
the infusion of BDNF	47134
the infusion	47134
BDNF	47150
the rostroventral medulla	47174
it	47206
nociceptive mechanisms	47229
BDNF infusions	47276
this area -LRB- Guo et al. , 2006 -RRB-	47296
this area	47296
Guo	47307
et al. , 2006	47311
et al.	47311
2006	47319
BDNF infusion to the red nucleus	47332
BDNF infusion	47332
the red nucleus	47349
an effect on sensory thresholds	47382
an effect	47382
sensory thresholds	47395
the absence of cell transplantation	47417
the absence	47417
cell transplantation	47432
such a mechanism involving the medulla	47454
such a mechanism	47454
the medulla	47481
the sensitization effect of dorsal horn neurons	47513
the sensitization effect	47513
dorsal horn neurons	47541
OECs transplants	47564
conclusion	47585
our transplants of highly enriched LP-OECs	47606
our transplants	47606
highly enriched LP-OECs	47625
the injured spinal cord	47657
astrocyte hypertrophy	47693
they	47716
regeneration of rubrospinal axons	47739
regeneration	47739
rubrospinal axons	47755
the lesion site	47792
addition	47812
the combination of highly enriched OECs with BDNF infusion to the red nucleus	47822
the combination	47822
highly enriched OECs with BDNF infusion to the red nucleus	47841
highly enriched OECs	47841
BDNF infusion to the red nucleus	47867
BDNF infusion	47867
the red nucleus	47884
the functional recovery	47923
lowered sensory thresholds	47970
the forepaw	48000
These adverse effects of a combinatorial treatment	48013
These adverse effects	48013
a combinatorial treatment	48038
contrast	48084
the beneficial effects	48107
other combinations	48142
Lu	48162
et al. , 2003	48165
et al.	48165
2003	48173
Nikulina et al. , 2004	48179
Nikulina	48179
et al. , 2004	48188
et al.	48188
2004	48196
Pearse et al. , 2004	48202
Pearse	48202
et al. , 2004	48209
et al.	48209
2004	48217
Fouad et al. , 2005	48223
Fouad	48223
et al. , 2005	48229
et al.	48229
2005	48237
Steinmetz et al. , 2005	48243
Steinmetz	48243
et al. , 2005	48253
et al.	48253
2005	48261
BDNF infusion into the midbrain	48268
BDNF infusion	48268
the midbrain	48287
axonal growth -LRB- Kobayashi et al. , 1997 ; Kwon et al. , 2002 -RRB-	48342
axonal growth	48342
Kobayashi	48357
et al. , 1997 ; Kwon et al. , 2002	48367
et al.	48367
1997 ; Kwon et al.	48375
1997	48375
Kwon et al.	48381
Kwon	48381
et al.	48386
2002	48394
therapeutic potential in its present form	48419
therapeutic potential	48419
its present form	48444
it	48464
fine motor recovery	48477
Alternatives	48498
the enhancement of the intrinsic growth response of these neurons	48515
the enhancement	48515
the intrinsic growth response of these neurons	48534
the intrinsic growth response	48534
these neurons	48567
that	48592
adverse effects	48622
combinations	48652
the observed changes in motor and sensory function after combination therapy	48672
the observed changes	48672
motor and sensory function after combination therapy	48696
motor and sensory function	48696
combination therapy	48729
the necessity for extensive sensory	48759
the necessity	48759
extensive sensory	48777
motor testing	48799
candidate combination strategies	48816
some benefits	48876
Acknowledgements F. Bretzner	48898
a Fonds de Recherche en Sante du Quebec -LRB- FRSQ -RRB-	48941
a Fonds de Recherche	48941
Sante du Quebec -LRB- FRSQ -RRB-	48965
Sante du Quebec	48965
FRSQ	48982
Canadian Institutes of Health Research -LRB- CIHR -RRB- post-doctoral fellowship	48992
Canadian Institutes of Health Research -LRB- CIHR -RRB-	48992
Canadian Institutes	48992
Health Research -LRB- CIHR -RRB-	49015
Health Research	49015
CIHR	49032
post-doctoral fellowship	49038
This work	49064
-LRB- CIHR -RRB-	49088
Christopher	49096
Dana Reeve Foundation and International Spinal Research Trust	49112
We	49175
Tigran Bajgoric , Clarrie Lam , Miranda Richter and Darren Sutherland	49198
Tigran Bajgoric	49198
Clarrie Lam	49215
Miranda Richter	49228
Darren Sutherland	49248
technical assistance	49270
Abbreviations BDA , biotinylated dextran amine	49293
Abbreviations BDA	49293
Abbreviations	49293
BDA	49307
dextran amine	49325
BDNF , brain-derived neurotrophic factor	49340
BDNF	49340
brain-derived neurotrophic factor	49346
CGRP , calcitonin gene-related peptide	49381
CGRP	49381
calcitonin gene-related peptide	49387
FBS , fetal bovine serum	49420
FBS	49420
fetal bovine serum	49425
GFAP , glial fibrillary acidic protein	49445
GFAP	49445
glial fibrillary acidic protein	49451
GFP , green fluorescent protein	49484
GFP	49484
green fluorescent protein	49489
LP , lamina-propria	49516
LP	49516
lamina-propria	49520
NF , neurofilament	49536
NF	49536
neurofilament	49540
NGF , nerve growth factor	49555
NGF	49555
nerve growth factor	49560
OB , olfactory bulb	49581
OB	49581
olfactory bulb	49585
OEC , olfactory ensheathing cells	49601
OEC	49601
olfactory ensheathing cells	49606
P ⁄ S , penicillin ⁄ streptomycin	49635
P ⁄ S	49635
penicillin ⁄ streptomycin	49642
PBS , phosphate-buffered saline	49669
PBS	49669
phosphate-buffered saline	49674
SERT , serotonin transporter	49701
SERT	49701
serotonin transporter	49707
Sub-P , substance-P	49730
Sub-P	49730
substance-P	49737
TH , tyrosine hydroxylase	49750
TH	49750
tyrosine hydroxylase	49754
Tub , beta-III-tubulin	49776
Tub	49776
beta-III-tubulin	49781
Veh , vehicle	49799
Veh	49799
vehicle	49804
References	49813
Amador , M.J. & Guest , J.D. -LRB- 2005 -RRB-	49824
Amador , M.J. & Guest	49824
J.D. -LRB- 2005 -RRB-	49846
J.D.	49846
2005	49852
An appraisal of ongoing experimental procedures in human spinal cord injury	49858
An appraisal	49858
ongoing experimental procedures in human spinal cord injury	49874
ongoing experimental procedures	49874
human spinal cord injury	49909
J. Neurol .	49935
Phys .	49946
Ther. , 29 , 70 -- 86 .	49952
Ther.	49952
29 , 70 -- 86	49959
29	49959
70 -- 86	49963
Au , E. & Roskams	49970
A.J.	49988
2003	49994
Olfactory ensheathing cells	50000
the lamina propria in vivo and in vitro	50031
the lamina propria	50031
vivo	50053
Glia , 41 , 224 -- 236 .	50072
Glia	50072
41 , 224 -- 236	50078
41	50078
224 -- 236	50082
A.J. -LRB- 2007 -RRB- SPARC from olfactory ensheathing cells	50180
A.J. -LRB- 2007 -RRB- SPARC	50180
2007	50186
olfactory ensheathing cells	50203
Schwann cells	50242
neurite outgrowth	50267
spinal cord repair	50298
J. Neurosci. , 27 , 7208 -- 7221 .	50318
J. Neurosci.	50318
27 , 7208 -- 7221	50332
27	50332
7208 -- 7221	50336
K.J. -LRB- 2001 -RRB- Neurotrophic	50442
2001	50448
migratory properties of an olfactory ensheathing cell line	50471
migratory properties	50471
an olfactory ensheathing cell line	50495
Glia , 33 , 225 -- 229 .	50531
Glia	50531
33 , 225 -- 229	50537
33	50537
225 -- 229	50541
2005	50649
Dose-dependent beneficial and detrimental effects	50655
ROCK inhibitor Y27632 on axonal sprouting	50708
ROCK inhibitor Y27632	50708
axonal sprouting	50733
axonal	50733
functional recovery after rat spinal cord injury	50754
functional recovery	50754
rat spinal cord injury	50780
Exp .	50804
Neurol. , 196 , 352 -- 364 .	50809
Neurol.	50809
196 , 352 -- 364	50818
196	50818
352 -- 364	50823
Christensen , M.D. & Hulsebosch	50832
C.E. -LRB- 1997 -RRB- Spinal cord injury and anti-NGF treatment	50864
C.E.	50864
1997	50870
Spinal cord injury and anti-NGF treatment	50876
changes in CGRP density and distribution	50929
changes	50929
CGRP density and distribution	50940
the dorsal horn in the rat	50973
the dorsal horn	50973
the rat	50992
Exp .	51001
Neurol. , 147 , 463 -- 475 .	51006
Neurol.	51006
147 , 463 -- 475	51015
147	51015
463 -- 475	51020
Y.	51140
2005	51144
BDNF from microglia	51150
BDNF	51150
microglia	51160
the shift in neuronal anion gradient underlying neuropathic pain	51177
the shift	51177
neuronal anion gradient underlying neuropathic pain	51190
neuronal anion gradient	51190
neuropathic pain	51225
Nature , 438 , 1017 -- 1021 .	51243
Nature	51243
438 , 1017 -- 1021	51251
438	51251
1017 -- 1021	51256
Dobkin , B.H. , Curt , A. & Guest , J. -LRB- 2006 -RRB-	51267
Dobkin , B.H. , Curt , A. & Guest , J.	51267
2006	51303
Cellular transplants in China	51309
Cellular transplants	51309
China	51333
observational study	51340
the largest human experiment in chronic spinal cord injury	51365
the largest human experiment	51365
chronic spinal cord injury	51397
Neurorehabil	51425
Repair , 20 , 5 -- 13 .	51447
Repair	51447
20 , 5 -- 13	51455
20	51455
5 -- 13	51459
D.D. -LRB- 2005 -RRB- Combining Schwann cell bridges	51540
D.D. -LRB- 2005 -RRB- Combining	51540
2005	51546
Schwann cell bridges	51562
olfactory-ensheathing glia grafts with chondroitinase	51587
olfactory-ensheathing glia grafts	51587
chondroitinase	51626
locomotor recovery	51650
complete transection of the spinal cord	51675
complete transection	51675
the spinal cord	51699
J. Neurosci. , 25 , 1169 -- 1178 .	51716
J. Neurosci.	51716
25 , 1169 -- 1178	51730
25	51730
1169 -- 1178	51734
Franssen , E.H.	51745
Franssen	51745
E.H.	51755
Bree , F.M. & Verhaagen	51764
J. -LRB- 2007 -RRB- Olfactory ensheathing glia	51788
J.	51788
2007	51792
Olfactory ensheathing glia	51798
their contribution to primary olfactory nervous system regeneration	51826
their contribution	51826
primary olfactory nervous system regeneration	51848
their regenerative potential	51898
transplantation	51937
the injured spinal cord	51958
Brain Res .	51983
Brain	51983
Res	51989
Rev. , 56 , 236 -- 258 .	51994
Rev.	51994
56 , 236 -- 258	52000
56	52000
236 -- 258	52004
Guest , J. , Herrera , L.P. & Qian , T. -LRB- 2006 -RRB-	52013
Guest	52013
J. , Herrera , L.P. & Qian , T. -LRB- 2006 -RRB-	52020
J. , Herrera , L.P. & Qian , T.	52020
2006	52050
recovery	52062
segmental neurological function	52074
a tetraplegic patient	52109
transplantation of fetal olfactory bulb-derived cells	52141
transplantation	52141
fetal olfactory bulb-derived cells	52160
Spinal Cord , 44 , 135 -- 142 .	52196
Spinal Cord	52196
44 , 135 -- 142	52209
44	52209
135 -- 142	52213
Guo , W. , Robbins , M.T. , Wei , F. , Zou , S. , Dubner , R. & Ren , K.	52222
2006	52286
Supraspinal brain-derived neurotrophic factor signaling	52292
a novel mechanism for descending pain facilitation	52349
a novel mechanism	52349
descending pain facilitation	52371
J. Neurosci. , 26 , 126 -- 137 .	52401
J. Neurosci.	52401
26 , 126 -- 137	52415
26	52415
126 -- 137	52419
Heppenstall , P.A. & Lewin , G.R. -LRB- 2001 -RRB- BDNF but not NT-4	52428
Heppenstall , P.A. & Lewin , G.R. -LRB- 2001 -RRB- BDNF	52428
Heppenstall , P.A. & Lewin	52428
G.R. -LRB- 2001 -RRB- BDNF	52455
G.R.	52455
2001	52461
BDNF	52467
NT-4	52480
normal flexion reflex plasticity and function	52501
normal flexion reflex plasticity	52501
function	52538
Proc	52548
Natl Acad .	52554
Sci	52565
USA , 98 , 8107 -- 8112 .	52570
USA	52570
98 , 8107 -- 8112	52575
98	52575
8107 -- 8112	52579
Song	52686
Y. , Hao , W. , Pang , S. & Sun	52692
J. -LRB- 2003 -RRB- Influence	52721
2003	52725
patients ' age	52744
patients '	52744
functional recovery	52761
transplantation of olfactory ensheathing cells into injured spinal cord injury	52787
transplantation	52787
olfactory ensheathing cells into injured spinal cord injury	52806
olfactory ensheathing cells	52806
injured spinal cord injury	52839
Chin	52867
Med	52873
J. -LRB- Engl . -RRB-	52878
J.	52878
Engl .	52882
, 116 , 1488 -- 1491 .	52888
, 116 , 1488	52888
1491	52900
Jenkins , R. , Tetzlaff , W. & Hunt , S.P. -LRB- 1993 -RRB-	52906
Jenkins , R. , Tetzlaff , W. & Hunt , S.P.	52906
1993	52946
Differential expression	52952
immediate early genes in rubrospinal neurons following axotomy in rat	52979
immediate early genes	52979
rubrospinal neurons following axotomy in rat	53004
rubrospinal neurons	53004
axotomy in rat	53034
axotomy	53034
rat	53045
Eur	53050
J. Neurosci. , 5 , 203 -- 209 .	53055
J. Neurosci.	53055
5 , 203 -- 209	53069
5	53069
203 -- 209	53072
Jin , Y. , Fischer , I. , Tessler , A. & Houle	53081
J.D.	53124
2002	53130
Transplants of fibroblasts genetically modified	53136
Transplants	53136
fibroblasts genetically modified	53151
fibroblasts	53151
BDNF	53195
axonal regeneration	53208
supraspinal neurons following chronic spinal cord injury	53233
supraspinal neurons	53233
chronic spinal cord injury	53263
Exp .	53291
Neurol. , 177 , 265 -- 275 .	53296
Neurol.	53296
177 , 265 -- 275	53305
177	53305
265 -- 275	53310
S.W. -LRB- 1999 -RRB- Brain-derived neurotrophic factor	53442
S.W.	53442
1999	53448
Brain-derived neurotrophic factor	53454
nociceptive sensory inputs and NMDAevoked responses in the rat spinal cord	53498
nociceptive sensory inputs	53498
NMDAevoked responses in the rat spinal cord	53529
NMDAevoked responses	53529
the rat spinal cord	53553
J. Neurosci. , 19 , 5138 -- 5148 .	53574
J. Neurosci.	53574
19 , 5138 -- 5148	53588
19	53588
5138 -- 5148	53592
Keyvan-Fouladi , N. , Raisman , G. & Li , Y. -LRB- 2003 -RRB-	53603
Keyvan-Fouladi , N. , Raisman , G. & Li , Y.	53603
2003	53645
Functional repair	53651
the corticospinal tract	53672
delayed transplantation of olfactory ensheathing cells in adult rats	53699
delayed transplantation	53699
olfactory ensheathing cells in adult rats	53726
olfactory ensheathing cells	53726
adult rats	53757
J. Neurosci. , 23 , 9428 -- 9434 .	53769
J. Neurosci.	53769
23 , 9428 -- 9434	53783
23	53783
9428 -- 9434	53787
W.	53879
1997	53883
BDNF and NT-4 ⁄ 5	53889
BDNF	53889
NT-4 ⁄ 5	53898
NT-4	53898
⁄ 5	53903
atrophy of rat rubrospinal neurons	53915
atrophy	53915
rat rubrospinal neurons	53926
cervical axotomy	53956
GAP-43 and Talpha1-tubulin mRNA expression	53984
axonal regeneration	54040
J. Neurosci. , 17 , 9583 -- 9595 .	54061
J. Neurosci.	54061
17 , 9583 -- 9595	54075
17	54075
9583 -- 9595	54079
2002	54184
Survival and regeneration of rubrospinal neurons 1 year after spinal cord injury	54190
Survival and regeneration	54190
rubrospinal neurons 1 year after spinal cord injury	54219
rubrospinal neurons	54219
1 year	54239
spinal cord injury	54252
Proc	54272
Natl Acad .	54278
Sci	54289
USA , 99 , 3246 -- 3251 .	54294
USA	54294
99 , 3246 -- 3251	54299
99	54299
3246 -- 3251	54303
Li , Y. , Field , P.M. & Raisman	54314
G. -LRB- 1997 -RRB- Repair	54345
1997	54349
adult rat corticospinal tract by transplants of olfactory ensheathing cells	54365
adult rat corticospinal tract	54365
transplants of olfactory ensheathing cells	54398
transplants	54398
olfactory ensheathing cells	54413
Science , 277 , 2000 -- 2002 .	54442
Science	54442
277 , 2000 -- 2002	54451
277	54451
2000 -- 2002	54456
Li , Y. , Field , P.M. & Raisman , G. -LRB- 1998 -RRB-	54467
Li , Y. , Field , P.M. & Raisman , G.	54467
1998	54502
Regeneration	54508
adult rat corticospinal axons	54524
transplanted olfactory ensheathing cells	54565
transplanted olfactory ensheathing	54565
cells	54600
J. Neurosci. , 18 , 10514 -- 10524 .	54607
J. Neurosci.	54607
18 , 10514 -- 10524	54621
18	54621
10514 -- 10524	54625
Lipson , A.C. , Widenfalk , J. , Lindqvist , E. , Ebendal , T. & Olson , L.	54638
2003	54707
Neurotrophic properties of olfactory ensheathing glia	54713
Neurotrophic properties	54713
olfactory ensheathing glia	54740
Exp .	54768
Neurol. , 180 , 167 -- 171 .	54773
Neurol.	54773
180 , 167 -- 171	54782
180	54782
167 -- 171	54787
I.	54889
1999	54893
Transplants of fibroblasts genetically modified	54899
Transplants	54899
fibroblasts genetically modified	54914
fibroblasts	54914
BDNF	54958
regeneration of adult rat rubrospinal axons and recovery of forelimb function	54971
regeneration	54971
adult rat rubrospinal axons and recovery of forelimb function	54987
adult rat rubrospinal axons	54987
adult rat	54987
rubrospinal axons	54997
recovery of forelimb function	55019
recovery	55019
forelimb function	55031
J. Neurosci. , 19 , 4370 -- 4387 .	55050
J. Neurosci.	55050
19 , 4370 -- 4387	55064
19	55064
4370 -- 4387	55068
Lopez-Vales , R. , Garcia-Alias , G. , Fores , J. , Navarro , X. & Verdu , E.	55079
2004	55150
Increased expression	55156
cyclo-oxygenase 2 and vascular endothelial growth factor	55180
cyclo-oxygenase 2	55180
lesioned spinal cord by transplanted olfactory ensheathing cells	55240
lesioned spinal cord	55240
transplanted olfactory ensheathing cells	55264
transplanted olfactory ensheathing	55264
cells	55299
J. Neurotrauma , 21 , 1031 -- 1043 .	55306
J. Neurotrauma	55306
21 , 1031 -- 1043	55322
21	55322
1031 -- 1043	55326
Lu , J. , Feron , F. , Ho , S.M. , Mackay-Sim , A. & Waite	55337
P.M.	55390
2001	55396
Transplantation of nasal olfactory tissue	55402
Transplantation	55402
nasal olfactory tissue	55421
partial recovery in paraplegic adult rats	55453
partial recovery	55453
paraplegic adult rats	55473
Brain Res. , 889 , 344 -- 357 .	55496
Brain Res.	55496
889 , 344 -- 357	55508
889	55508
344 -- 357	55513
Lu , J. , Feron , F. , Mackay-Sim , A. & Waite	55522
P.M. -LRB- 2002 -RRB- Olfactory ensheathing cells	55565
P.M.	55565
2002	55571
Olfactory ensheathing cells	55577
locomotor recovery	55613
delayed transplantation into transected spinal cord	55638
delayed transplantation	55638
transected spinal cord	55667
Brain , 125 , 14 -- 21 .	55691
Brain	55691
125 , 14 -- 21	55698
125	55698
14 -- 21	55703
Lu , P. , Jones , L.L. , Snyder , E.Y. & Tuszynski	55710
M.H. -LRB- 2003 -RRB- Neural stem cells	55757
M.H.	55757
2003	55763
Neural stem cells	55769
neurotrophic factors	55810
extensive host axonal growth	55843
spinal cord injury	55878
Exp .	55898
Neurol. , 181 , 115 -- 129 .	55903
Neurol.	55903
181 , 115 -- 129	55912
181	55912
115 -- 129	55917
A.	56026
Lindsay , R.M. , Wilkinson , G.A. & Woolf	56030
C.J. -LRB- 1999 -RRB- Neurotrophins :	56070
C.J.	56070
1999	56076
Neurotrophins	56082
modulators of tactile stimulus-induced inflammatory pain hypersensitivity	56131
modulators	56131
tactile stimulus-induced inflammatory pain hypersensitivity	56145
Proc	56206
Natl Acad .	56212
Sci	56223
USA , 96 , 9385 -- 9390 .	56228
USA	56228
96 , 9385 -- 9390	56233
96	56233
9385 -- 9390	56237
Nash , H.H. , Borke , R.C. & Anders	56248
J.J.	56282
2002	56288
Ensheathing cells and methylprednisolone	56294
Ensheathing cells	56294
methylprednisolone	56316
axonal regeneration and functional recovery	56343
the lesioned adult rat spinal cord	56390
J. Neurosci. , 22 , 7111 -- 7120 .	56426
J. Neurosci.	56426
22 , 7111 -- 7120	56440
22	56440
7111 -- 7120	56444
Nikulina , E. , Tidwell , J.L. , Dai , H.N. , Bregman , B.S. & Filbin	56455
M.T.	56519
2004	56525
The phosphodiesterase inhibitor rolipram delivered after a spinal cord lesion	56531
The phosphodiesterase inhibitor rolipram	56531
a spinal cord lesion	56588
axonal regeneration and functional recovery	56618
axonal regeneration	56618
functional recovery	56642
Proc	56663
Natl Acad .	56669
Sci	56680
USA , 101 , 8786 -- 8790 .	56685
USA	56685
101 , 8786 -- 8790	56690
101	56690
8786 -- 8790	56695
2006	56797
adult axon regeneration promoted by olfactory ensheathing cells	56825
adult axon regeneration	56825
olfactory ensheathing cells	56861
a new role for matrix metalloproteinase 2	56890
a new role	56890
matrix metalloproteinase 2	56905
J. Neurosci. , 26 , 5347 -- 5359 .	56933
J. Neurosci.	56933
26 , 5347 -- 5359	56947
26	56947
5347 -- 5359	56951
J.	57052
2007	57056
BDNF production by olfactory ensheathing cells	57062
BDNF production	57062
olfactory ensheathing cells	57081
axonal regeneration of cultured adult CNS neurons	57124
axonal regeneration	57124
adult CNS neurons	57156
Neurochem	57175
Int. , 50 , 491 -- 498 .	57186
Int.	57186
50 , 491 -- 498	57192
50	57192
491 -- 498	57196
M.B. -LRB- 2004 -RRB- cAMP and Schwann cells	57301
M.B.	57301
2004	57307
cAMP and Schwann cells	57313
axonal growth and functional recovery	57344
spinal cord injury	57388
Nat .	57408
Med. , 10 , 610 -- 616 .	57413
Med.	57413
10 , 610 -- 616	57419
10	57419
610 -- 616	57423
Pezet , S. & McMahon , S.B. -LRB- 2006 -RRB- Neurotrophins	57433
Pezet , S. & McMahon	57433
S.B. -LRB- 2006 -RRB- Neurotrophins	57454
S.B.	57454
2006	57460
Neurotrophins	57466
mediators and modulators of pain	57481
mediators and modulators	57481
pain	57509
Annu	57515
Rev. Neurosci. , 29 , 507 -- 538 .	57521
Rev. Neurosci.	57521
29 , 507 -- 538	57537
29	57537
507 -- 538	57541
2001	57645
Differential regulation	57651
NGF receptors	57678
primary sensory neurons by adjuvant-induced arthritis in the rat	57695
primary sensory neurons	57695
adjuvant-induced arthritis in the rat	57722
adjuvant-induced arthritis	57722
the rat	57752
Pain , 90 , 113 -- 125 .	57761
Pain	57761
90 , 113 -- 125	57767
90	57767
113 -- 125	57771
M. -LRB- 2002 -RRB- BDNF	57868
2002	57872
sensory neuron synaptic activity	57893
a facilitation of GABA transmission in the dorsal horn	57929
a facilitation	57929
GABA transmission in the dorsal horn	57947
GABA transmission	57947
the dorsal horn	57968
Mol	57985
Cell .	57990
Neurosci. , 21 , 51 -- 62 .	57996
Neurosci.	57996
21 , 51 -- 62	58007
21	58007
51 -- 62	58011
Plunet , W. , Streijger , F. , Lam , C.K. , Lee , J.H.T. , Liu , J. & Tetzlaff	58018
W. -LRB- 2008 -RRB- Dietary restriction	58089
W. -LRB- 2008 -RRB- Dietary	58089
2008	58093
restriction	58107
spinal cord injury	58133
functional recovery	58161
Exp .	58182
Neurol. , 213 , 28 -- 35 .	58187
Neurol.	58187
213 , 28 -- 35	58196
213	58196
28 -- 35	58201
Priestley , J.V. , Michael , G.J. , Averill , S. , Liu , M. & Willmott , N.	58208
2002	58277
Regulation	58283
nociceptive neurons	58297
nerve growth factor and glial cell line derived neurotrophic factor	58320
nerve growth factor and glial cell line	58320
neurotrophic factor	58368
J. Physiol .	58394
Pharmacol. , 80 , 495 -- 505 .	58406
Pharmacol.	58406
80 , 495 -- 505	58418
80	58418
495 -- 505	58422
Ramer , L.M. , Au , E. , Richter , M.W. , Liu , J. , Tetzlaff , W. & Roskams	58431
A.J. -LRB- 2004a -RRB- Peripheral olfactory ensheathing cells	58500
A.J.	58500
2004a	58506
Peripheral olfactory ensheathing cells	58513
scar and cavity formation	58559
regeneration	58597
spinal cord injury	58616
J. Comp .	58636
Neurol. , 473 , 1 -- 15 .	58645
Neurol.	58645
473 , 1 -- 15	58654
473	58654
1 -- 15	58659
Ramer , L.M. , Borisoff , J.F. & Ramer	58665
M.S. -LRB- 2004b -RRB- Rho-kinase inhibition	58702
M.S.	58702
2004b	58708
Rho-kinase inhibition	58715
axonal plasticity	58746
cold hyperalgesia	58779
dorsal rhizotomy	58803
J. Neurosci. , 24 , 10796 -- 10805 .	58821
J. Neurosci.	58821
24 , 10796 -- 10805	58835
24	58835
10796 -- 10805	58839
Ramon-Cueto , A. , Plant , G.W. , Avila , J. & Bunge	58852
M.B.	58901
1998	58907
Long-distance axonal regeneration in the transected adult rat spinal cord	58913
Long-distance axonal regeneration	58913
the transected adult rat spinal cord	58950
olfactory ensheathing glia transplants	59002
J. Neurosci. , 18 , 3803 -- 3815 .	59042
J. Neurosci.	59042
18 , 3803 -- 3815	59056
18	59056
3803 -- 3815	59060
Ramon-Cueto	59071
A.	59084
Cordero , M.I. , Santos-Benito , F.F. & Avila , J. -LRB- 2000 -RRB-	59088
Cordero , M.I. , Santos-Benito , F.F. & Avila	59088
J. -LRB- 2000 -RRB-	59132
J.	59132
2000	59136
Functional recovery of paraplegic rats	59142
Functional recovery	59142
paraplegic rats	59165
motor axon regeneration in their spinal cords by olfactory ensheathing glia	59185
motor axon regeneration	59185
their spinal cords by olfactory ensheathing glia	59212
their spinal cords	59212
olfactory ensheathing glia	59234
Neuron , 25 , 425 -- 435 .	59262
Neuron	59262
25 , 425 -- 435	59270
25	59270
425 -- 435	59274
Richter , M.W. & Roskams , A.J. -LRB- 2008 -RRB-	59283
Richter , M.W. & Roskams , A.J.	59283
2008	59314
Olfactory ensheathing cell transplantation	59320
spinal cord injury : hype or hope	59373
spinal cord injury	59373
hype or hope	59393
hype	59393
Exp .	59407
Neurol. , 209 , 353 -- 367 .	59412
Neurol.	59412
209 , 353 -- 367	59421
209	59421
353 -- 367	59426
Richter , M.W. , Fletcher , P.A. , Liu , J. , Tetzlaff , W. & Roskams	59436
A.J. -LRB- 2005 -RRB- Lamina propria and olfactory bulb ensheathing cells	59500
A.J. -LRB- 2005 -RRB- Lamina propria	59500
A.J. -LRB- 2005 -RRB- Lamina	59500
2005	59506
propria	59519
olfactory bulb ensheathing cells	59531
differential integration and migration	59572
differential axon sprouting in the lesioned spinal cord	59623
differential axon	59623
the lesioned spinal cord	59654
J. Neurosci. , 25 , 10700 -- 10711 .	59680
J. Neurosci.	59680
25 , 10700 -- 10711	59694
25	59694
10700 -- 10711	59698
J. -LRB- 2003 -RRB-	59835
J.	59835
2003	59839
Ex vivo	59845
adenoviral vector-mediated neurotrophin gene transfer	59853
olfactory ensheathing glia	59910
effects	59938
rubrospinal tract regeneration , lesion size , and functional recovery	59949
rubrospinal tract regeneration	59949
lesion size	59981
functional recovery	59998
implantation in the injured rat spinal cord	60024
implantation	60024
the injured rat spinal cord	60040
J. Neurosci. , 23 , 7045 -- 7058 .	60069
J. Neurosci.	60069
23 , 7045 -- 7058	60083
23	60083
7045 -- 7058	60087
Sasaki , M. , Lankford , K.L. , Zemedkun , M. & Kocsis , J.D. -LRB- 2004 -RRB-	60098
Sasaki , M. , Lankford , K.L. , Zemedkun , M. & Kocsis , J.D.	60098
2004	60155
olfactory ensheathing cells	60172
the transected dorsal funiculus bridge the lesion and form myelin	60218
the	60218
dorsal funiculus bridge the lesion and form	60233
dorsal funiculus bridge	60233
the lesion and form	60257
J. Neurosci. , 24 , 8485 -- 8493 .	60285
J. Neurosci.	60285
24 , 8485 -- 8493	60299
24	60299
8485 -- 8493	60303
2006a	60398
Molecular reconstruction	60405
nodes	60433
Ranvier	60442
remyelination	60456
transplanted olfactory ensheathing cells in the demyelinated spinal cord	60473
transplanted olfactory ensheathing cells	60473
the demyelinated spinal cord	60517
the	60517
spinal cord	60534
J. Neurosci. , 26 , 1803 -- 1812 .	60547
J. Neurosci.	60547
26 , 1803 -- 1812	60561
26	60561
1803 -- 1812	60565
Sasaki , M. , Hains , B.C. , Lankford , K.L. , Waxman , S.G. & Kocsis , J.D.	60576
-LRB- 2006b -RRB- Protection of corticospinal tract neurons after dorsal	60645
-LRB- 2006b -RRB- Protection	60645
corticospinal tract neurons after dorsal	60667
corticospinal tract neurons	60667
dorsal	60701
spinal cord transection and engraftment of olfactory ensheathing cells	60708
spinal cord transection and engraftment	60708
olfactory ensheathing cells	60751
Glia , 53 , 352 -- 359 .	60780
Glia	60780
53 , 352 -- 359	60786
53	60786
352 -- 359	60790
2000	60875
CNS plasticity and assessment	60881
forelimb sensorimotor outcome	60914
unilateral rat models	60947
stroke , cortical ablation , parkinsonism and spinal cord injury	60972
stroke	60972
cortical ablation	60980
parkinsonism	60999
spinal cord injury	61016
Neuropharmacology , 39 , 777 -- 787 .	61036
Neuropharmacology	61036
39 , 777 -- 787	61055
39	61055
777 -- 787	61059
2005	61172
Chronic enhancement	61178
the intrinsic growth capacity	61201
sensory neurons combined with the degradation of inhibitory proteoglycans	61234
sensory neurons	61234
the degradation of inhibitory proteoglycans	61264
the degradation	61264
inhibitory proteoglycans	61283
functional regeneration of sensory axons	61315
functional regeneration	61315
sensory axons	61342
the dorsal root	61364
entry zone in the mammalian spinal cord	61380
entry zone	61380
the mammalian spinal cord	61394
J. Neurosci. , 25 , 8066 -- 8076 .	61421
J. Neurosci.	61421
25 , 8066 -- 8076	61435
25	61435
8066 -- 8076	61439
Tetzlaff , W. , Alexander , S.W. , Miller , F.D. & Bisby , M.A. -LRB- 1991 -RRB-	61451
Tetzlaff , W. , Alexander , S.W. , Miller , F.D. & Bisby , M.A.	61451
1991	61510
facial and rubrospinal neurons	61528
axotomy	61562
changes in mRNA expression for cytoskeletal proteins and GAP-43	61571
changes	61571
mRNA expression for cytoskeletal proteins and GAP-43	61582
mRNA expression	61582
cytoskeletal proteins and GAP-43	61602
J. Neurosci. , 11 , 2528 -- 2544 .	61636
J. Neurosci.	61636
11 , 2528 -- 2544	61650
11	61650
2528 -- 2544	61654
Verdu , E. , Garcia-Alias , G. , Fores , J. , Lopez-Vales , R. & Navarro	61665
X.	61732
2003	61736
Olfactory ensheathing cells transplanted in lesioned spinal cord	61742
Olfactory ensheathing cells	61742
lesioned spinal cord	61786
loss of spinal cord parenchyma	61815
loss	61815
spinal cord parenchyma	61823
functional recovery	61858
Glia , 42 , 275 -- 286 .	61879
Glia	61879
42 , 275 -- 286	61885
42	61885
275 -- 286	61889
-LRB- 2006 -RRB- Phenotypical analysis of adult rat	61977
-LRB- 2006 -RRB- Phenotypical analysis	61977
2006	61978
adult rat	62009
olfactory ensheathing cells on 3-D collagen scaffolds	62019
olfactory ensheathing cells	62019
3-D collagen scaffolds	62050
Neurosci	62074
Lett. , 401 , 65 -- 70 .	62084
Lett.	62084
401 , 65 -- 70	62091
401	62091
65 -- 70	62096
Whishaw , I.Q. , Pellis , S.M. , Gorny , B. , Kolb , B. & Tetzlaff , W.	62103
1993	62168
Proximal and distal impairments	62174
rat forelimb use in reaching follow unilateral pyramidal tract lesions	62209
rat forelimb use	62209
unilateral pyramidal tract lesions	62245
Behav	62281
Brain Res. , 56 , 59 -- 76 .	62288
Brain Res.	62288
56 , 59 -- 76	62300
56	62300
59 -- 76	62304
Xiao , M. , Klueber , K.M. , Guo , Z. , Lu , C. , Wang , H. & Roisen	62311
F.J. -LRB- 2007 -RRB- Human adult olfactory neural progenitors	62372
F.J.	62372
2007	62378
Human adult olfactory neural progenitors	62384
axotomized rubrospinal tract axonal reinnervation and locomotor recovery	62433
axotomized rubrospinal tract	62433
axonal reinnervation and locomotor recovery	62462
Neurobiol	62507
Dis. , 26 , 363 -- 374 .	62518
Dis.	62518
26 , 363 -- 374	62524
26	62524
363 -- 374	62528
Ye	62538
J.H. & Houle , J.D. -LRB- 1997 -RRB- Treatment	62542
1997	62562
the chronically injured spinal cord with neurotrophic factors	62581
the chronically injured spinal cord	62581
neurotrophic factors	62622
axonal regeneration	62655
supraspinal neurons	62680
Exp .	62701
Neurol. , 143 , 70 -- 81 .	62706
Neurol.	62706
143 , 70 -- 81	62715
143	62715
70 -- 81	62720
